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Cryptococcus deneoformans is a basidiomycetous yeast found in multiple habitats across 
the globe. The species is a causative agent of cryptococcosis, a disease in which the inhalation of 
spores leads to fungal colonization of the lungs in various hosts. Cryptococcosis may also 
progress to other organs, notably the brain, which can result in cryptococcal 
meningoencephalitis. Unchecked cryptococcal disease is invasive, disruptive, and highly lethal, 
resulting in 13%-73% mortality rates despite treatment and 100% mortality when left untreated. 
Treatment options for cryptococcal disease are limited, especially in underdeveloped countries 
bearing the brunt of cryptococcal mortality due to lack of effective antifungal drugs.  
The search for drug targets in the C. neoformans species complex is being driven by 
molecular research into conserved proteins, many of which play key roles in cell survival and/or 
virulent processes. Studying the function of such proteins often requires complex genetic 
manipulations either in vitro or in vivo. This thesis aimed to test a CRISPR-Cas9 gene editing 
system in C. deneoformans that could be used to induce damage in precise gene targets, and also 
design a modular gene cassette that could recombine at those damaged sites by manipulating the 
endogenous DNA repair mechanisms of the cell. Editing was successfully accomplished in the 
URA5 gene by disrupting and later excising the coding region by homology-driven 
recombination with a modular gene cassette. In addition, the promoter region of the DNA 
polymerase gamma gene, MIP1, a putative essential gene, was replaced with a copper-
repressible promoter, CTR4p, to attempt to convey evidence for its necessity and suitability as a 








CHAPTER I. INTRODUCTION 
1. Cryptococcus deneoformans – Description and significance 
The Cryptococcus neoformans species complex comprises seven species of 
basidiomycetous, medically relevant yeast.1,2 These species are the flagbearers for the 
Cryptococcus genus, which contains more than 30 species.3 The most clinically significant 
species of the complex are C. deneoformans, C. neoformans, and C. gatti. These organisms 
typically exist as single-celled, budding yeasts and are obligate aerobes. Under certain 
conditions, they can enter a sexual state in which hyphal structures and basidospores form.4 
These species have two mating archetypes (MAT), a and α; each operating in the fungus akin to 
opposing 'sexes.' Mating type is determined by approximately 20 genes and restricts sexual 
recombination to mutually exclusive MAT strains. These yeasts also exude a polysaccharide 
capsule that can vary in glycan content such that they can be classified into five distinct antibody 
response types, or serotypes – A, AD, B, C, and D.5 These serotypes were previously used to 
distinguish different subvarieties of C. neoformans that have now been segregated into seven 
species. Those serotypes largely coincide with some species: A and AD are found predominantly 
in C. neoformans, D in C. deneoformans, and B and C in C. gatti.1 
C. deneoformans (and also C. gatti and C. neoformans) have a series of notable 
characteristics that contribute to an opportunistic virulence in a variety of mammals, humans 
included.3 Some of these major characteristics include: the potential for melanin production, the 
capacity to survive at 37°C, and the presence of a complex extracellular polysaccharide capsule. 
C. deneoformans and its sister species induce Cryptococcosis, which manifests as a respiratory 
infection wrought by inhalation of cryptococcal basidiospores and/or heavily desiccated cells.6 







environments and/or flora. In most cases, the disease is either cleared by the host adaptive 
immune response or becomes asymptomatically latent. However, in the immunocompromised, 
this disease induces pulmonary symptoms as the yeast population goes unchecked. Most 
concerningly, this may lead to fungal sepsis as the yeast disseminates into the bloodstream from 
the lungs. Once systemic, cryptococcosis can manifest in various organs – notably the central 
nervous system. While the yeast cannot normally cross the blood-brain-barrier, MATα strains can 
manipulate endothelial cells to enter the brain, inducing a unique, highly lethal neurological 
disease, cryptococcal meningoencephalitis.3,7  
        Cryptococcal diseases are concerning due to poor patient outlook and limited 
treatment options. Without proper care, prognosis is dire. Non-treatment mortality rates of 100% 
have been observed within two weeks of clinical presentation. Primary chemotherapeutic 
regimens typically involve amphotericin B deoxycholate, fluconazole, flucytosine, and 
intraconazole. These drugs reliably reduce patient cryptococcal load; however, the treatments 
have few alternatives and can cause severe complications. Novel therapeutic options are needed 
given the risk of emerging, resistant cryptococcal strains and the complications posed by current 
treatments.8 Antimicrobial design revolves around the discovery of ‘drug targets’, which are 
typically gene products that are essential to the microbe’s survival and/or virulence in the host. 
Such cellular components are usually unique elements that distinguish it from humans. Essential 
genes can sometimes be difficult to delete for experimental study due to the important roles they 
play in the life of the microbe. An example of a drug target is ergosterol, a unique fungal sterol 
that integrates into fungal membranes and is required for proper fungal growth. The molecule 
and its underlying biosynthetic pathway are essential for fungal virulence trans-taxa, and as such, 







Amphotericin B is a drug that binds ergosterol and induces perforation of the fungal plasma 
membranes, ultimately killing the cell via cytoplasmic exsanguination. While it is effective 
against fungal pathogens like C. deneoformans, the similarity of the structure of ergosterol to 
mammalian sterols presumably contributes to the severe side-effects it causes in humans.10, 11 
Amphotericin B is, consequently, far from an ideal drug and is reserved for critical scenarios. 
However, as mentioned above, there are few alternatives for culling fungal pathogens in humans; 
hence the need for new drugs and drug targets. One method of studying a gene products’s 
candidacy as a drug target is by silencing the underlying gene’s expression by repressing its 
promoter in a conditional manner. For some drug targets, this can be the only method of showing 
essentiality due to the deleterious effects caused by lacking the gene product.3 Accordingly, 
promoter replacement is a useful technique to show the essentiality of a gene. That being said, 
gene necessity does not universally correlate to drug target candidacy. A drug target must be 
sufficiently different from any orthologous gene products in the host to minimize side-effects 
posed to the host. An ideal drug target is one that is necessary and has no similar components in 
humans. In order to probe for said drug targets, genetic manipulation is a primary method. 
 
2. Gene manipulation in Cryptococcus – Transformation and genetic functionalization 
 
The C. neoformans species complex has been extensively researched over the last 
century, establishing these yeasts as robust model organisms for molecular study.4, 6 Genomic 
data on C. neoformans and C. deneoformans is readily available due to whole-genome 
sequencing. Significant study into virulence mechanisms and mating types has additionally 







ease of culturing these free-living haploid yeasts gives researchers plentiful opportunities to 
probe cryptococcal genes for clinical relevance at both the in vitro and in vivo level. In vivo 
studies on cryptococcal gene function have been spearheaded by site-specific mutagenesis 
techniques.12, 13 To accomplish this, two transformation approaches – biolistics and 
electroporation – have been the primary methods to introduce gene editing systems into the 
yeasts.13, 14, 15 These systems typically insert exogenous DNAs by inducing damage in the 
genome that then activates the cell’s DNA repair mechanisms. This helps integrate the sequences 
into chromosomes in a relatively predictable, replicable manner. Such systems can be used to 
facilitate both gene knock-out or gene knock-in, allowing for a gene’s role in the fungal 
phenotype to be assayed by the presence or absence of the encoded protein or RNA.13 
Biolistic techniques have, until recently, been the go-to transformation method for 
Cryptococcus when seeking genomic integration of constructs.13 It features a combined 
exogenous DNA-delivery and endogenous DNA-damaging mechanism whereby DNA-coated 
microparticles are ballistically projected into living cells. These microparticles penetrate the 
yeast’s nucleus and induce chromosomal damage via the force of the collision.15 Although a 
reliable means of delivering DNA-based editing systems, transformation via biolistics carries a 
risk of producing unstable transformant strains. The instability is likely caused by a randomness 
of damage sites and high rates of episomal DNA expression.4,13 Further, biolistic approaches also 
tend to be hampered by the need for expensive equipment that is not readily available to most 
institutions.16 
Electroporation protocols were developed at a similar time to biolistics and posed 
themselves as relatively low cost transformation systems with comparable potential for en masse 







induce a variety of phenotypes. However, electroporation has a significantly reduced 
recombination efficiency relative to biolistics. Biolistic transformations across the C. neoformans 
species complex typically have a 1-10% recombination efficiency, with the rate increasing to a 
range of 2-50% in the C. neoformans species specifically. Electroporation on the other hand 
produced a 10-5 – 10-3% frequency when using similar systems, presumably caused by not 
inducing DNA damage during transformation.13 Despite the general inefficiency of 
electroporation in facilitating genomic integration, the ability to pair this with methods that can 
cause DNA damage by more precise mechanisms than biolistics have revitalized the technique. 
Targeted DNA damaging systems can be used to improve recombination rates, thereby 
alleviating electroporation’s aforementioned shortcomings. One method of creating site-specific 
DNA damage is via the use of Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-Cas9.13, 14 
Gene knockout and modification are reliable molecular methods to ascertain gene 
function in organisms. However, a problem associated with gene knockout studies is the 
deleterious effect caused by the disruption of an essential gene. One common technique used to 
get around this problem is the replacement of endogenous promoters by a regulatable promoter. 
Promoter replacement usually leaves the coding sequence (CDS) of a gene of interest untouched 
while the upstream regulatory elements are excised and regulatable replacements introduced. 
This has traditionally been done by assembling an in vitro construct that contained the CDS of a 
gene of interest fused with the 5’ untranslated region (UTR) of a regulatable gene, transforming 
it in, and then screening for gene product activity.18, 19, 20 However, the development of CRISPR-
Cas9 has allowed for promoter manipulation at the chromosomal level in vivo.14, 21 A number of 







neoformans and C. deneoformans genes. These promoters have been used in various in vivo 
promoter replacement studies.18,19, 20 Of the known conditional cryptococcal promoters, the one 
used in this study is the promoter of CTR4 gene (CTR4p). 
The CTR4 gene encodes a copper-specific transporter involved in cryptococcal virulence 
and copper homeostasis. 22, 23 The gene’s expression is regulated akin to the CTR4p mechanism 
studied in the fission yeast, Schizosaccharomyces pombe.24 In S. pombe, CTR4 transcription is 
regulated by upstream interactions with Cuf1, an innate transcription factor and sensor for 
intracellular copper concentrations.25 When intracellular copper ion concentrations are high, 
Cuf1 binds the ions and becomes conformationally inactive. When copper concentrations are 
low, Cuf1 becomes conformationally active and binds to copper-sensing elements (CuSE) in the 
genome. When Cuf1 interacts with a CuSE, downstream genes like CTR4 become upregulated, 
presumably as a long-term response to low copper in the cytosol.24, 25 Ory et al. found that 
CnCTR4p also contain CuSE-like sequences and can be used to manipulate recombinant gene 
expression in C. neoformans.18 Waterman et al. demonstrated that a series of virulent C. 
neoformans Serotype A strains contained a Cuf1 homolog that manipulates CTR4 expression 
based on copper availability. 24 This homolog effectively regulates the gene akin to SpCTR4. Ory 
et al. further demonstrated that CnCTR4p can induce altered regulation via a copper-dependent 
mechanism in modified genes transformed into C. neoformans and C. deneoformans. However, 
transcriptional expression from the CnCTR4p constructs was unstable as the plasmids lacked a 
cryptococcal origin of replication, ultimately meaning the plasmids were not maintained in vivo.  
Integrating the construct in the genome could rectify this problem. Therefore, CnCTR4p could be 
used to control chromosomal genes in a regulatable manner when used with recombination-







manipulating the environmental conditions of the cell, which facilitates the investigation of gene 
essentiality without having to rely on plasmid constructs. CRISPR-Cas9 is one such tool that can 
be used to facilitate recombination in the cryptococcal genome. 
 
3. Cryptococcus and CRISPR-Cas9 – Description and significance 
 
CRISPR-Cas9 is a relatively simple, programmable gene editing system derived from an 
adaptive immune response in the bacterium Streptococcus pyogenes.26 In its original form, 
CRISPR-Cas9 recognizes and damages invading bacteriophage DNA by using an RNA guidance 
system. This system is produced from a genetic array of partial gene sequences derived from 
viral DNA. Those arrays arise from prior bacteriophage attacks and get transcribed into CRISPR 
RNAs (crRNA) that are complementary to a sequence in the injected viral genome. The locus 
also contains a gene for CRISPR-associated protein 9 (CAS9), an endonuclease capable of 
inducing double-stranded DNA (dsDNA) breaks some three or four base pairs away from an 
NGG sequence called a Protospacer Adjacent Motif (PAM). Cas9 does not bind to DNA on its 
own and requires a conserved trans-activating RNA (tracrRNA) to activate and guide the enzyme 
to it crRNA-designated target. 
 
Figure 1 – CRISPR locus from S. pyogenes. The tracrRNA is produced from a single gene upstream of 
the cas operon, which itself is upstream of the crDNA array. Each repeat in the array is derived from 
partial viral DNA sequences and conveys a form of adaptive immunity against previously encountered 








 The tracrRNA acts as a bridge between the Cas9 endonuclease and the crRNA-DNA complex. 
To facilitate the formation of a protein-RNA-DNA complex, the tracrRNA contains a Cas9 
binding sequence and also a complementary stretch to the crRNA. This complementation allows 
the two RNAs to bind together and form a RNA-protein complex with Cas9. Thereby, the 
crRNA-viral DNA complex is bridged to the RNA-Cas9 complex via the tracrRNA. The fully 
assembled DNA-RNA-protein complex induces dsDNA breaks in the viral DNA and adaptively 
switches guides to target different sequences in the viral genome. The crRNAs target DNAs that 
have a PAM just off its 5’ end of the complementary sequence; this is because the PAM is 
absolutely necessary for appropriate Cas9 activity. Therefore, crRNAs must target sequences 
with an adjacent PAM in order to be effective. Ultimately, the CRISPR activity results in 
degradation of the infecting DNA, averting lytic or latent bacteriophage infection cycles. 26,27  
CRISPR-Cas9 has been adapted for eukaryotic use by expressing the CAS9 gene using 
species-specific promoters.27 Synthetic tracrRNA-crRNA fusions, acting as single guide RNA 
sequences (sgRNAs), can then be supplied – typically co-transformed alongside the modified 
CAS9, such that precise DNA damage can be induced by the translation products. Accordingly, 
only those two genes are then needed for CRISPR-Cas9 activity. This system is easy to program, 
easy to transform, and capable of multiplexed targeting of PAM-adjacent DNA sequences in in 
vivo experiments.28 
CRISPR-Cas9 has become a recent utility in cryptococcal gene manipulation thanks to its 
ability to drive homology-directed DNA repair. In other yeasts such as Saccharomyces 
cerevisiae, vector systems have been developed whereby exogenous DNA can be cloned and 
propagated in the yeast using plasmids with an inserted origin of replication.29 These plasmids 







species complex presumably because they are maintained in S. cerevisiae and not C. neoformans. 
At present, inserting a cryptococcal origin of replication into a plasmid is unfeasible given its 
large size.30 As such, a stable plasmid system in cryptococcal species is not yet viable. 
Consequently, the best means of improving expression stability is by inserting exogenous DNA 
into the cryptococcal genome. This has traditionally been done by homology-driven 
recombination using homologous repair templates and biolistics. 
 The C. deneoformans and its sister species do not readily uptake foreign DNA like S. 
cerevisiae. Insertion of DNA in Cryptococcus requires the manipulation of the organisms’ DNA 
repair mechanisms to facilitate chromosomal recombination. That being said, it has been found 
that there is a chance for off-target recombinations between the chromosomes and 
nonhomologous DNAs. These tend to occur when using biolistic transformations, which carries a 
risk of random genomic damage due to the violence of the mechanism. There is some debate as 
to how extensive this is but the risk is present none-the-less.31 To achieve targeted recombination 
in cryptococcal cells, homologous sequences can be attached to the flanks of a recombinant 
DNA fragments to facilitate homology-driven recombination.14 To further improve targeted 
recombination between the cryptococcal genome and exogenous DNA, it was found that 
disabling the organism’s non-homologous end joining (NHEJ) repair mechanism improves 
faithful insertion. NHEJ knockout strains were created by knocking out Ku70 and Ku80 gene 
function, thereby forcing the yeast to rely on homology-driven repair alternatives.32 Homology-
driven DNA repair is highly accurate and site-specific due to the system’s reliance on repair 
templates with significant homology to the damaged site. Accordingly, targeted DNA damage, 





As an alternative to Ku-knock out and artificial chromosome engineering, CRISPR-Cas9 
has been used to facilitate site-specific recombinations without using biolistic transformation. 
DNA breakage has been found to correlate to the insertion of exogenous DNA into the 
cryptococcal genome, meaning that targeted damage can be used to improve genomic 
recombination.31 CRISPR-Cas9 is an adaptive DNA damaging system that can precisely damage 
chromosomes at specific sites. The damage necessitates repair, which researchers can manipulate 
to insert DNA into the chromosome.14,27 Thereby, CRISPR-Cas9 is being used to improve 
recombination in C. deneoformans by allowing researchers to take advantage of non-homologous 
and homology-driven DNA repair.14,33  
  CRISPR-Cas9 has been shown to be a novel, precise technique for targeted DNA 
damage in Cryptococcus while also revitalizing electroporation. By pairing electroporation with 
a ‘programmable’ DNA damaging system, homology-drive recombination with exogenous 
constructs has been shown by Fan and Lin (2018) to be more efficient than biolistics across C. 
neoformans and C. deneoformans.14 Recombination efficiencies targeting CnADE2 have reached 
nearly 50% in wildtype strains, matching the effectiveness of contemporary biolistic 
techniques.13,14 The procedure, Transient CRISPR-Cas9 Coupled with Electroporation (TRACE), 
was a modification of a transient CRISPR-Cas9 system developed for Candida albicans.34 
TRACE induces homology-driven recombination by co-transforming CRISPR constructs that are 
unstably expressed alongside a recombination template for a gene of interest. NHEJ still occurs 
in this system, though homology-directed DNA repair becomes the predominant mechanism of 
cryptococcal DNA repair. Thus, NHEJ knock-out is not required and recombination between the 
chromosome and construct(s) readily occurs. The CRISPR-system is presumed to quickly 





degradation prevents long-term expression of the CRISPR-Cas9 DNAs, which is thought to 
confer a risk of off-target DNA damage.14,16 Accordingly, these transient CRISPR systems may 
mitigate potential off-target DNA damage caused by constitutive over-expression. The extra-
chromosomal nature of the aforementioned constructs is, in theory, unable to recombine with the 
genome, thereby allowing the instability of the episomal DNAs to work in the method’s favor. 
Transient CRISPR systems can be used to induce high rates of chromosomal integration of co-
transformed homologous constructs.13,16 Fan and Lin used a single gene disruption to test their 
constructs.14 In this project, I have used a modified version of their TRACE system to target 
other genes in C. deneoformans to test the validity of the system, and to expand its utility by 
integrating a promoter replacement mechanism along with a fluorescent tag. 
 
The aims of this project were as follows: 
(I) Construct a series of modular gene cassettes that may be used episomally or 
for chromosomal insertion. 
(II) Establish a transient CRISPR-Cas9 system capable of disruption of the URA5 
gene.  
(III) Use the transient CRISPR-Cas9 system developed in (II) to replace the 
endogenous MIP1 promoter with a conditional alternative. 
Aim I sought to design and assemble a series of constructs containing a regulatable promoter and 
a fluorescent tag that could be modified easily to control various aspects of the expression of a 
gene of choice. Aim II sought to establish a DNA editing system that can reliably and cheaply 
induce targeted DNA damage in C. deneoformans such that constructs like those assembled in 
Aim I can be recombined with chromosomal targets. Aim III sought to modify the presumably 





also demonstrating that the DNA editing system developed in Aim II could be used to modify the 
regulatory elements outside of genes. The CRISPR-Cas9 system developed in Aim II will be 
used in future studies of gene function via the aforementioned recombination of chromosomal 
targets by modifying the constructs derived from Aim I with flanking sequences homologous to 






CHAPTER II. MATERIALS AND METHODS 
1. Fungal cultures used and growth conditions. Cryptococcus deneoformans JEC21 MAT-α 
(Serotype D, IBCN43) was used for CRISPR-Cas9 validation in Aim II and III experiments. C. 
neoformans var. grubii KN99 MAT-α (Serotype A, IBCN2) was used as a genomic source for 
fragments in Aim I experiments. Stock strains were cultivated on Yeast Extract-Peptone-
Dextrose (YPD) agar and in broth cultures (Yeast Extract 10g/L, Tryptone 20g/L, Dextrose 
20g/L) at 30°C with 1-2 and 2-3 day incubation times respectively. Broth cultures were 
incubated at 30°C using a shaking incubator at 200RPM. Cultures were supplemented with 
100mg/mL ampicillin to select for fungal growth. Cultures transformed in Aim II were 
supplemented with 100mg/mL G418 to select for NEOR expression and then restreaked onto 5-
fluoroorotic acid (5-FOA). 5-FOA plates were comprised of: 50mL Yeast Nitrogen Base w/o 
amino acids (BD 291940) (Base 6.7g/0.1L), 5µg/mL adenine (1mL of 5mg/mL per 100mL), and 
1.2µg/mL uracil (600µL of 2mg/mL per 100mL) agar supplemented with 50mL 1mg/1mL 5-
fluoroortic acid (100mg/100mL), 4% dextrose (Mallinckrodt 3908-04), and 5µM sodium 
hydroxide (Fisher S320-500).  Cultures transformed in Aim III were supplemented with 
100mg/mL G418 and 400mg/mL BCS (Fisher Scientific AC164060010) but then restreaked onto 
YPD with 25µM CuSO4 (Thermofisher BP346) and 1mM ascorbic acid (Sigma-Aldrich A7506). 
 
2. Bacterial cultures used and growth conditions. Escherichia coli NEB 5- α High Efficiency 
Competent cells (New England Biolabs [NEB] C2987I) were used for most Aim I cassette 
cloning transformations. The NEOR-CTR4p-MIP1 Nterm plasmid; that construct was 
transformed into NEB Turbo Competent E. coli (NEB C2984I). All strains were cultivated on 
Lysogeny agar (LA) and broth (LB) cultures (Yeast Extract 5g/L, Tryptone 10g/L, NaCl 10g/L) 





incubator at 225RPM. Cultures transformed in Aim I were supplemented with 100µg/mL 
ampicillin and or kanamycin to select for constructs being cloned. 
 
3. Plasmid ‘MiniPrep’ extraction and purification. Propagated plasmids were extracted from E. 
coli hosts via the WizardPlus SV Minipreps DNA Purification System using a Quick 
Centrifugation Protocol.36 Success was gauged by 0.8% TAE-agarose ethidium bromide gel 
electrophoresis and purifications were stored at -20°C. 
 
4. Cryptococcus genomic sequence acquisition. Gene sequences for CdURA5, CdMIP1, 
CnCTR4p were obtained using the FungiDB Sequence Retrieval tool. Sequence IDs were 
CNG03730, CNB00310, and CKF44_00979 respectively. FungiDB Releases 51 and 52 were 
used over the course of the project. 
 
5. Genomic DNA extraction from Cryptococcus. A modified version of the extraction method 
from Boggs (2017), which was originally described by Bose and Doering (2011), was used for 
genomic DNA extraction.37,38 Approximately 3mL of broth culture was inoculated from YPD 
plates followed by an overnight incubation (~17-20hr) for harvest the next day. Cells were 
pelleted via centrifugation and resuspended in 0.5mL of Extraction Buffer (500mM Tris-HCl 
pH8, 20mM EDTA, 1% SDS). 0.5mL of sterile 425-600µm glass beads were then added. The 
mixtures were agitated for 10 min. at room temperature followed by 3-5 min. intervals until 50-
80% cellular lysis was confirmed by compound microscopy. The lysed cells were incubated at 
70°C for 10 min., buffered with 0.2mL of 5M potassium acetate and 0.15mL of 5M sodium 





removed and mixed with 0.45mL of 99% HPLC-grade chloroform followed by ten minutes of 
14.5rpm centrifugation. The aqueous phase was transferred to a separate tube, supplemented 
with 0.2mL of 30% PEG8000 in 1.5M sodium chloride solution, and incubated on ice for 10 
min.  The resultant nucleic acid pellet was resuspended in 50µL of ~65°C ultrapure H2O. 
Successful extractions were confirmed with ethidium bromide 0.8% TAE-agarose gel 
electrophoresis at 100V for 30 minutes. Extracts were then stored at -20°C. 
 
6. PCR amplification and purification of modular gene expression cassette reagents.  1.816kb 
NEOR, 0.650kb CnCTR4p, 0.771kb GFP, 0.108kb MIP1 predicted MLS, and 1.105kb MIP1 N-
terminal fragment sequences were amplified for use as reagents in Methods 7. Primers were used 
in such a way to insert complementary restriction enzyme sites on each sequence flank. All 
amplicons were visualized on appropriate TAE-agarose ethidium bromide gel electrophoresis 
with corresponding DNA ladders. All PCR reactions had a 5µL negative control sample taken 
from the reaction mixture before template DNA(s) were added. All PCR products were purified 
using the Wizard Plus SV Gel and PCR Clean-Up System Centrifugation Quick protocol.39 
 
 6. a. PCR amplification of CTR4p, NEOR, and GFP. PCR fragments were amplified 
using either Q5 or Phusion proof-reading (NEB M0530S) polymerases and 2µM dNTPs. The 
NEOR, CnCTR4p, and GFP sequences were amplified with 450µM primer concentration and 
~2.5-10ng pIBB236 and pIBB314 as templates for CnCTR4p and NEOR/GFP respectively. PCR 

















98°C for 30s, [98°C for 10s, 
63°C for 15s, 72°C for 60s]x28, 









98°C for 15s, [98°C for 10s, 
65°C for 10s, 72°C for 30s]x28, 
72°C for 2’, hold at 4°C 
 
 6. b. PCR amplifications of CnMIP1 MLS, CnCYC1t, CnURA5t, and CdMIP1 fragments.  
PCR fragments were amplified using Phusion proof-reading polymerases and 2µM dNTPs. 
The MIP1 predicted MLS, URA5t, CYC1t, and MIP1 1.105kb N-terminus sequence PCRs used 
100-200µM primer concentration and~10-20ng C. neoformans KN99 genomic DNA extract as a 


















98°C for 30s, [98°C for 10s, 67.2°C [62-
69°C Gradient] for 10s, 72°C for 15s]x28, 




98°C for 30s, [98°C for 15s, 60.4°C [54-
62°C Gradient] for 10s, 72°C for 15s]x28, 




Same as URA5t 
MIP1 Nterm √ 
BLO337/338 
(200µM) 
95°C for 30s, [95°C for 15s, 61.3°C [57-
62°C Gradient] for 20s, 72°C for 45s]x34, 






Same as MIP1 Nterm 
 
7. Ligation of modular gene expression cassettes using T4 DNA ligase. C. deneoformans cassette 
constructs and modified variants were assembled in vitro using T4 DNA ligation. The reagent 
fragments were assembled into a 3.261kb core cassette that was modified with a variety of 
modular fragments. Modifications were made in the form of: The putative CnMIP1 MLS being 
added just 5’ of GFP, a STOP-229bp CnCYC1 terminator (CnCYC1t) just 3’ of GFP, an 215bp 
STOP-CnURA5 terminator (CnURA5t) just 3’ of GFP, and a 1.105kb MIP1 N-terminal fragment 
replacing the GFP CDS.  All ligations were incubated overnight at 16°C. 
 A 3.261kb NEOR-CTR4p-GFP gene expression cassette was assembled in a 





BamHI digested 1.817kb NEOR gene, a BamHI-SpeI digested 0.650kb cryptococcal CTR4 
promoter (CTR4p), and a 0.771kb GFP coding frame. Purified sequences were ligated in 1:1 and 
1:3 molar vector-to-insert conditions using ~50ng of HindIII-XbaI digested vector alongside a 
negative control in 20µL reactions detailed below.  
To create pIBB327, a SpeI digested 108bp CnMIP1 predicted MLS fragment was ligated 
into a Shrimp Alkaline Phosphatase-treated [30min. 37°C; 65°C heat-inactivation for 20min.] 
pIBB326 construct.  Purified sequences were ligated in 1:2 and 1:4 molar vector-to-insert 
conditions using ~50ng SpeI digested vector. 
Two different terminator fragments, URA5t (212bp) and CYC1t (226bp), were added to 
the SAP-treated (as above) XbaI site of pIBB327. 1:2 and 1:4 molar vector-to-insert ratios using 
~50ng of the digested vector were used. The final plasmids were named pIBB328 and 
pIBB329/330 respectively. 
pIBB331 and pIBB332 respectively contained the No-MLS,+URA5t and +CYC1t 
cassettes. They were constructed by removing the MLS fragments from plasmids pIBB328 and 
pIBB329, which were digested with SpeI such that the MLS was separated from the gel purified 
vector fragment. ~50ng of the SpeI-digested vectors were self-ligated. 
Four plasmids containing an MLS and a terminator were created (pIBB333, 334, 335, and 
336) using pIBB207 as template, using the conditions described above. 
The MIP1 N-terminal 1.105kb fragment was inserted into the SpeI and XbaI sites of the 
pIBB326 plasmid using 1:1 and 1:3 vector to insert molar ratios using ~10ng of digested vector. 
 
8. Sanger sequencing. DNA samples were sent to Genewiz for Sanger sequencing. All samples 





was purified and quantified such that 2ng/µL/kb was added to each sample. 25µM primer 
concentrations were included in all samples. 
 
9. sgDNA crRNA sequence acquisition and in silico evaluation. CRISPR-Cas9 sgDNA targets 
for URA5 and MIP1 were found and evaluated for off-target potential, cutting efficiency, and 
potential problems using the Eukaryotic Pathogen CRISPR guide RNA/DNA Design Tool.40 All 
sgDNA search parameters were left default and are as follows: SpCas9 RNA Guided Nuclease 
(SpCas9: 20nt gRNA, NGG PAM on 3’ end selection), microhomology search off, conserved 
region search off, guide RNA search left default, on-target search parameters left default, off-
target search parameters left default, HDR repair template parameters left default, C. 
deneoformans genome selected (Fungi>C. neoformans JEC21 FungiDB-26), and URA5/MIP1 
FASTA sequences put into the Sequence box. crDNA sequences/candidates were generated and 
candidates with the highest relative CRISPR efficiency scores used. All generated crDNA 
sequences are listed by the tool with their targeted PAM included; for sgDNAs made using the 
BLO264 and 265 bridge primers, this PAM was left in the sequence to generate a 23bp crDNA 
fragment, for all other sgDNA bridge primers, the PAM was excised/not added into the bridge 
primer sequence. Retaining the 3nt PAM sequence was found to drastically reduce CRISPR 
effectiveness as was seen in Results II; optimized sgDNA design requires the sgDNA not having 
a PAM complement in its sequence. 
 
10.  Acquisition of GPD-CAS9 and sgDNA scaffold vectors.  GPDp-CAS9 endonuclease was 
amplified from pXL1-CAS9-HYG while the single guide DNA scaffold (sgDNA) was amplified 






11. PCR amplification and purification of sgDNA scaffold, CdU6p, sgDNA, and CAS9.  The 
CRISPR-Cas9 gene editing system was assembled by PCR amplification of the various pieces 
using Phusion polymerase. All amplicons were visualized on appropriate TAE-agarose ethidium 
bromide gel electrophoresis with corresponding DNA ladders. PCR reactions had a 5µL negative 
sample taken from the reaction mixture before template DNA(s) were added. PCR products were 
purified using the Wizard Plus SV Gel and PCR Clean-Up System.39 
Reactions for both the 108bp sgDNA scaffold and 275bp CdU6p sequences used 2µM 
dNTP and 200µM primers concentrations (see BLO263/264/265/328/329/330/342/343/344 for 
sgDNA scaffold forward primers). The CAS9 reaction was supplemented with 1M Betaine 
(Sigma B0300-1VL) and sgDNA reaction with 5% DMSO (NEB B0515A) to facilitate proper 
priming. sgDNAs were assembled by overlap PCR; all others were standard PCRs.41 The sgDNA 
scaffold and CdU6p reactions used ~2-10ng of pYF515 and 10-30ng of JEC21 gDNA as 
templates respectively. The CAS9 reaction used 10-25ng of purified pXL1-CAS9-HYG plasmid 
as a template. The sgDNA overlap used ~10ng of gel purified CdU6p DNA and ~30ng of gel 
purified sgDNA scaffold, which was a ~1:1 molar ratio, as templates.  A temperature gradient 
program was found to more reliably amplify the sequences relative to a blanket well temperature. 
The gradient program also allowed the sgDNA scaffold and CdU6p PCRs to be run with the 
same program, hence the Gradient’s usage rather than standard temperature setting. 50µL or 
100µL reactions were set up depending on the quantity of sgDNA needed; ~1-3µg and 3-5µg 













U6p Phusion X 
BLO260/261 
(200µM) 
95°C for 30s, [9t°C for 15s, 
58.8°C [50-61°C gradient] for 
15s, 72°C for 30s]x34, 72°C 







95°C for 30s, [95°C for 15s, 
56.7°C [50-61°C gradient] for 
15s, 72°C for 30s]x34, 72°C 






95°C for 30s, [95°C for 15s, 
56.7°C [50-61°C gradient] for 
15s, 72°C for 30s]x34, 72°C 






95°C for 30s, [95°C for 15s, 
60°C for 15s, 72°C for 4’]x30, 
72°C for 10’, hold at 4°C.. 
 
 
12. PCR assembly of C. deneoformans HDR templates. Phusion overlap PCR was used to 





amplicons were visualized on appropriate TAE-agarose ethidium bromide gel electrophoresis 
with corresponding DNA ladders. All PCR reactions had a 5µL negative sample taken from the 
reaction mixture before template DNA(s) were added. All products were purified using the 
Wizard Plus SV Gel and PCR Clean-Up System using a modification of the DNA Purification by 
Centrifugation Quick protocol.39 
 
12. a. Amplifications of homology arm reagents for HDR templates. The PCRs for the 5’ 
103bp and 3’ 119bp URA5 CDS, 5’ 500bp and 3’ 563bp URA5 CDS, 5’ 545bp and 3’ 522bp 
URA5 UTR, 5’ MIP1 726bp UTR homology arms used 2µM dNTP and 200-400µM primer 
concentrations. The MIP1 arm required 5% DMSO and 1M betaine supplement to properly 
amplify. ~10-20ng of JEC21 genomic DNA extract was used as a template. PCR conditions and 














98°C for 30s, [98°C for 15s, 
61.4°C [58-67°C gradient] for 
15s, 72°C for 30s]x34, 72°C for 






98°C for 30s, [98°C for 15s, 





15s, 72°C for 30s]x34, 72°C for 






98°C for 30s, [98°C for 15s, 
63.5°C [58-67°C gradient] for 
15s, 72°C for 30s]x34, 72°C for 












95°C for 30s, [95°C for 15s, 
62°C [60-64°C gradient] for 
15s, 72°C for 30s]x34, 72°C for 












95°C for 30s, [95°C for 15s, 
61.3°C [57-64°C gradient] for 
20s, 72°C for 45s]x28, 72°C for 
4’, hold at 4°C 
 
12. b. Amplification of cassettes for HDR templates. The amplifications of 1.895kb NEOR 
gene, 3.546kb NEOR-CTR4p-GFP-CYC1t, 3.650kb NEOR-CTR4p-MLS-GFP-CYC1t, and 





concentrations ~5-10ng of purified plasmids were used as templates: pIBB314 was the template 
for NEOR; pIBB329 and 332 were respective templates for the two +CYC1t cassettes; pIBB334 
was the template for the MIP1 Nterm cassette. was used as a template. PCR conditions and 














98°C for 30s, [98°C for 15s, 
65°C for 15s, 72°C for 1’]x28, 






95°C for 30s, [95°C for 15s, 
62°C [60-64°C gradient] for 
15s, 72°C for 80s]x34, 72°C for 






95°C for 30s, [95°C for 15s, 
62.5°C [60-64°C gradient] for 
20s, 72°C for 90s]x30, 72°C for 
6’, hold at 4°C 
 
12. c. Overlap PCR to assemble HDR templates. The amplifications for the 2.117kb and 
2.958kb NEOR gene with ~100bp and ~500bp flanks homologous to the URA5 CDS; 4.543kb 
NEOR-CTR4p-GFP-CYC1t and 4.637kb NEOR-CTR4p-MLS-GFP-CYC1t cassettes with flanks 





the MIP1 5’ CDS and 5’ UTR used 2µM final dNTP and 200µM primer concentrations. ~1-25ng 
of purified homology arms and ~8-10ng of cassettes were used as templates. PCR conditions and 
















98°C for 30s, [98°C for 15s, 
62.3°C for 20s, 72°C for 















95°C for 30s, [95°C for 15s, 
62°C [60-64°C gradient] for 
15s, 72°C for 80s]x34, 72°C 







95°C for 30s, [95°C for 15s, 
61°C [60-64°C gradient] for 
20s, 72°C for 110s]x30, 






13. Transformation of C. deneoformans via electroporation. Fresh cultures of JEC21 were grown 
on YPD from glycerol stocks four days before the day of this protocol; culture freshness was 
required to minimize the appearance of colonies with spontaneous mutations on nonselective 
media. Colonies 2 days post-plating were used to inoculate ~15mL (or x3 5mls cultures) of YPD 
broth; these cultures were then incubated overnight (~17-20hrs). The next morning, cells from 
this starter culture were used to inoculate a 100mL YPD culture to a density of ~0.2 OD600nm. 
The culture was incubated for ~4-6hr until an OD of about 0.6-0.7; this correlates to a cell 
density of >3.5x107 cells/mL. The 100mL culture was pelleted in an Eppendorf Centrifuge 
5810R rotor chilled to 4°C, spinning for 5 minutes at 4000rpm. The pellets were resuspended in 
~10mL of chilled ultra-pure H2O each, pooled, and brought to a wash volume of ~50mL. This 
wash was pelleted and washed once more as described above. After the second wash, cells were 
resuspended in ~10mL of Electroporation Buffer ([EB] 10mM Tris-HCl pH7.5, 1mM 
magnesium chloride, 270mM sucrose), supplemented with 0.2mL of 1M DTT (Fluka Analytical 
43816), and then brought to a volume of 50mL with EB buffer. The mixture was incubated on 
ice for ~10 minutes before being pelleted as described above. The pellet was resuspended in 
fresh EB before being pelleted a final time. The supernatant was decanted and the pellet was 
resuspended in the remaining EB into a thick slurry. ~100µL of the slurry was pipetted into UV-
sterilized, chilled electroporation 0.2cm gap cuvettes (Bio-Rad 1652082); culture was carefully 
tapped to the bottom of the cuvette until the entire bottom was coated. 6µL of sample DNA was 
then added and gently mixed into the culture. Cuvettes were electroporated with a Bio-Rad 
GenePulser Xcell at 0.5kV, 25µF, and ∝Ω. Time constants of 35-117ms were found to correlate 
to the best transformations. The cultures were resuspended in 1mL of chilled YPD media and 





were then transferred to 1.5mL Eppendorf tubes for pelleting, a 1mL ultra-pure H2O wash, and 
resuspended in 0.3mL of ultrapure H2O. Cells were plated on appropriate selective media and 
incubated for 2-3 days at 30˚C.  
CAS9 and sgDNA PCR products produced in Methods 11 were electroporated into C. 
deneoformans. Quantification was done with the NanoDrop ND-1000 Spectrophotometer and 
ethidium bromide agarose electrophoresis. Initial trials used 170ng CAS9 and 100ng sgDNA in 
~6µl volumes of ultra-pure water (Appendix 5); all Aim II and III experiments used 1µg and 
700ng of CAS9 and sgDNA, respectively. The DNA was vacuum-dried using an Eppendorf 
Vacufuge 5301 Concentrator with default conditions at room temperature for 35-60 minutes; 
dried pellets were then resuspended in 6µL of ultra-pure water. Samples in concentrator were 
parafilm covered with a small aeration perforation. 
For the URA5 NHEJ experiment, 2µg of the NEOR–CTR4p-GFP-CYC1t gene expression 
cassette was co-transformed with the CAS9 and sgDNAs for use as a non-homologous drug 
selection marker.  For the URA5 HDR experiments, 2µg of a 1.895kb NEOR gene with 5’ and a 
3’ URA5 homologous sequences and/or NEOR-CTR4p-(MLS)-GFP-CYC1t with 5’ 525bp and 3’ 
502bp CdURA5 flanks were used as the repair template.  For promoter replacement of MIP1, 
2µg of 4.383kb NEOR-CTR4p-CdMIP1 N-term was used in the electroporation. 
 
14. PCR Assays of URA5 and MIP1. 5-FOA and NEO resistant colonies were subjected to 
genomic extraction protocols described in Methods 5 in order to be screened for URA5 amplicon 
size. NEO resistant colonies growing on copper-depleted media were similarly extracted from to 
screen MIP1 amplicon size. This method was used to ascertain successful gene editing using the 





on appropriate TAE-agarose ethidium bromide gel electrophoresis with corresponding DNA 
ladders. All PCR reactions had a 5µL negative sample taken from the reaction mixture before 
template DNA(s) were added. 
The GoTaq PCR kit (Promega catalog M3001) was used to amplify the 1.023kb URA5 
CDS along with some of the 5’ UTR to screen for NEOR URA5 disruption template 
recombination and NHEJ-disrupted locus size. Taq 2x Mastermix PCR kit (NEB catalog 
M0270L) was used to screen for a variety of targets in URA5 and MIP1: a 383bp URA5 fragment 
containing the sg265, 328, 329, and 330 cut sites; a 1.834kb fragment containing the entire 
URA5 locus; insertion of CTR4p into the URA5 locus; and insertion of CTR4p into the MIP1 
locus. All reactions used 2µM final dNTP and 200µM primer concentrations. ~10-20ng of 
JEC21 dual-resistance phenotype genomic DNA extract was used as a template. PCR conditions 













95°C for 30s, [95°C for 30s, 52°C for 15s, 
68°C for 30s (short) and 6.5’ (long)]x34, 







95°C for 30s, [95°C for 10s, 56.1°C [50-
60°C gradient] for 15s, 72°C for 3’]x30, 





URA5 locus NEB 2x 
BLO316/317 
(200µM) 
95°C for 30s, [95°C for 15s, 55.2°C [54-
57°C gradient] for 20s, 68°C for 5’]x30, 







95°C for 30s, [95°C for 15s, 55.2°C [54-
57°C gradient] for 20s, 68°C for 3’]x30, 






95°C for 30s, [95°C for 15s, 53°C for 20s, 






95°C for 30s, [95°C for 15s, 57°C for 20s, 
68°C for 4’]x30, 68°C for 6’, hold at 4°C 
 
15. GFP expression tracking with EVOS Widefield fluorescent microscopy. Assays for GFP 
signal were done using an EVOS microscope with a GFP light cube filter. These were an attempt 
to qualify CTR4p-GFP-terminator in vivo function. Constructs from Methods 7 were transformed 
into JEC21 using electroporation protocols described in Methods 13. Transformant colonies were 
inoculated in ~1.5mL YPD-NEO overnight [~18hr]. 500µL of the culture was used to inoculate a 
1.5mL YPD-NEO-400µM BCS culture. 1mL of the YPD-NEO-BCS culture was spun down and 
then resuspended in Complete Minimal Medium-NEO-BCS. Samples were run alongside one 
wild-type C. deneoformans JEC21 negative control. 
+CYC1t and +CYC1t,TEL constructs were linearized with Sca-I and transformed 
episomally using electroporation. Growth conditions were identical to those described above and 





oil immersion, image captured, and then deconvoluted using the open-source ‘Fiji Is Just Imagej’ 
(FIJI) Iterative Deconvolve plug-in software.42 
To test for differences in chromosomal GFP expression, +CYC1t constructs assembled in 
Methods 7 were inserted into the URA5 locus via HDR. Growth conditions were identical to 
those described above but were run alongside a YPD-NEO duplicate cultures without BCS. The 
lack of BCS leaves copper unchelated and theoretically represses the CTR4 promoter, hence no 
signal was expected and allowed the duplicates to be run as negatives. Samples with presumptive 






CHAPTER III. RESULTS 
 
1. Construction of a series of modular gene cassettes for Cryptococcus. 
 
 Gene expression cassette cloning can be a time-intensive task that scales with the 
complexity of the cassette. Having more components necessitates more ligation, more cloning, 
and screening. While useful as vehicles for the expression of various genes and/or fragments in 
vivo, cassettes require careful design and planning to ensure proper assembly. As part of this 
project, a modular gene expression cassette featuring a selection marker, followed by a promoter, 
and finalized by an expression tracker was designed. Restriction sites were structured such that 
orientation and assembly would be streamlined. The unique sites would also allow for each 
fragment in the cassette to be a potential insertion or excision site, allowing for a stream-lining of 
cassette design for future experiments (Fig 2).  
Figure 2 – Schematic for modular gene expression cassettes designed in this project. 
 
1. a. Design and assembly of a modular gene cassette for homology-driven recombination  
 
In order to create a template to insert into the Cas9 cut-site by homology driven DNA 
repair, a modular gene cassette was designed.  This modular cassette contained a neomycin 
resistance gene (NEOR) for selection, the copper-repressible CnCTR4 promoter for regulated 





Homologous arms to a “gene of interest” (Protein of Interest or POI) could be added to this 
cassette, making this a versatile system for genetic manipulation. 
 
 
Figure 3 – Schematic for the modular gene cassette showing the position and sizes of the three fragments. 
The CTR4p and GFP fragments reside within unique BamHI-SpeI and SpeI-XbaI sites, respectively.  The 
GFP in this cassette does not contain a stop codon so that a gene of interest can be expressed in-frame.  
This cassette can be used to add 5’ and 3’ regions homologous to ‘Protein of Interest’ (POI) by overlap 
PCR. Arrows denote primers used for amplifying the fragments. 
 
The cassette was synthesized and inserted within the HindIII-XbaI sites of the pCR2.1 TOPO 
plasmid using a multi-fragment ligation technique.  The NEOR fragment was amplified from 
plasmid pIBB314 with primers BLO291 and BLO292 containing HindIII and BamHI sites.  The 
CTR4p fragment was amplified from pIBB236 with primers BLO293 and BLO294 containing 
BamHI and SpeI sites. The GFP fragment was amplified from plasmid pIBB314 using primer 
BLO295 and BLO296 containing SpeI and XbaI sites. The PCR fragments (Fig. 4) were digested 
with the appropriate restriction enzymes, purified, and ligated into the HindIII-XbaI digested 
vector (see Methods 7). Two different vector-to-insert molar ratios, 1:1 and 1:3, were used for 






10 colonies from each ligation transformation, were analyzed by restriction digests. A HindIII-
XbaI digestion should yield three fragments of sizes 3.819kb, 2.236kb, and 1.019kb, as shown by 
the Virtual Cutter (Fig. 5A). This pattern is found only in colony #5.  Similar results were 
obtained for the HindIII-BamHI, BamHI-SpeI, and SpeI-XbaI digests (see Fig 5 legend for 
details). Sanger sequencing with primers BLO291-296 confirmed the sequence identity and 
reading frame of the 1.817kb NEOR gene, the 0.65kb CTR4p, and 0.774kb GFP CDS (see 
Appendix 3.b-3.i).  
 
 
Figure 5 – Double digests of vectors obtained from 1:3 molar ligation transformants with accompanying 





SpeI-XbaI. Arrows denote faint bands in Construct #5 well. #5 contained all desired fragments. All 
visualizations were done using 0.8%TAE- agarose ethidium bromide gels with 1kb NEB DNA ladder. 
 
Electroporation into the wild type C. deneoformans JEC21 strain demonstrated that 
transformation with the construct conferred NEOR phenotype when using both linearized 
plasmid and purified whole-cassette amplicon (not shown). This transformant was frozen as 
pIBB326, and the map of the plasmid containing the complete cassette is shown in Fig 6.   This 






Figure 6 – Plasmid map of the cassette plasmid (pIBB326).  The 7074bp plasmid has a pCR2.1 TOPO 
backbone.  The NEOR, CTR4p, and GFP sequences are shown in blue, orange, and green, respectively.  







1. b. Addition of a putative MLS from CnMIP1 into the SpeI site of the modular gene cassette 
  
The original modular cassette contained no special localization signals for the expressed 
proteins. To ascertain the necessity of nuclear-encoded mitochondrial proteins like PolG, a 
Mitochondrial Localization Signal (MLS) needed to be added to the N-terminal of the GFP 
reading frame (Fig 7). 
 
 
Figure 7 – Plasmid map of the cassette plasmid containing the MIP1 MLS in-frame with the GFP 
sequences.  The MLS sequence was inserted into the SpeI site in between the CTR4p and GFP. 
  
The predicted MLS from C. neoformans MIP1 were amplified with BLO311 and 
BLO318. These primers contained SpeI restriction sites so that the resulting PCR fragment could 
be cloned into the SpeI site in-frame with the GFP gene using a 1:4 molar vector-to-insert 
ligation ratio.  Orientation and presence of the MLS was confirmed by PCR assays of 15 
transformant colonies using two separate reactions: one with the forward CTR4p primer 





reverse GFP (BLO296, see Appendix 1 for primers). The CTR4p-MLS PCR would yield a 
776bp amplicon only if the CTR4p was 5’ to the MLS. Similarly, the MLS-GFP PCR would 
yield an 883bp product only if the MLS was correctly situated and in the proper orientation. All 
15 samples were subjected to the GFP PCR assay, eight of which yielded amplicons of correct 
size (Fig 8A). Those eight were then subjected to the CTR4p-MLS PCR assay, and all eight 
yielded a PCR product of the expected size (Fig 8B).  
 
 
Figure 8 – MLS orientation PCR assays. (A) 0.8% TAE-agarose ethidium bromide gel visualization of 
MLS-GFP PCR using MLS forward primer and reverse GFP primer. Expected product size was 883bp. 
Visualized with 1kb NEB DNA ladder run at 100V for 30min. Cassette schematic included for reference; 
yellow boxes flanking the MLS denote the SpeI sites used for ligation. (B) 2% TAE-agarose ethidium 
bromide gel visualization CTR4p-MLS PCR using CTR4p forward primer and reverse MLS primer. 







Two colonies, #13 and #15, were sequenced with primers BLO293, BLO311, and BLO318 to 
confirm sequence identity and orientation of the MLS (Appendix 3.h,i). 
Colony #13 that was confirmed to have the correct insert by PCR and sequencing was saved as 
pIBB327. pIBB327 was later used to assemble the terminator-containing cassette variants. 
 
1. c. Creating modular gene cassettes with terminator fragments  
 
The original modular cassette featured a GFP reading frame without a stop codon or a 
downstream terminator so that it could be used to tag the N-terminal of a protein of interest (Fig 
3).  However, in order to test for conditional expression of GFP with the CTR4p copper-
repressible promoter, terminators and a stop-codon needed to be added for proper GFP 
expression.  A literature search for terminator sequences used in yeast molecular biology 
revealed that the CYC1 terminator (CYC1t) had previously been utilized to drive transcription of 
modified genes in S. cerevisiae.43,44 A URA5 terminator (CnURA5t) had been used in an algae 
model but seemingly not in yeast models.45 To see if the CnURA5 3’ UTR could be used as a 
short transcription terminator, a 215bp fragment was captured by primers that inserted flanking 
XbaI sites. CnURA5 is ~500bp upstream from the next gene in the KN99 chromosome, 
accordingly we went with a fairly limited fragment to screen for sufficiency with GFP 
expression. The 3’ UTR of CnCYC1 is less crowded but small fragments had been shown to be 
sufficient in S. cerevisiae; a 229bp fragment of the CnCYC1 3’ UTR was accordingly amplified 
with primers that also added XbaI sites to the flanks.44 The XbaI sites would allow for insertion 
of the UTR fragments into the corresponding site in the pIBB326 and 327 cassettes. A TAA stop 





Appendix 1) for the two terminators. The CnCYC1 and CnURA5 terminators (CnCYC1t and 




Figure 9 – Plasmid maps of terminator-containing cassette plasmids. (A) pIBB328 +MLS,+URA5t 
cassette (B) pIBB329 +MLS,+CYC1t cassette. (C) pIBB331 +URA5t cassette (D) pIBB332 +CYC1t 
cassette. The terminators were inserted into the unique XbaI site of the cassette, and contained a 5’-TAA 
stop codon for GFP. 
  
Amplicons were gel purified and digested with XbaI alongside appropriate cassette 
plasmids. Ligation conditions described in Methods 7 were used to assemble the constructs. 24 
colonies, 12 transformed with pIBB329, 12 with pIBB332, were sampled for NdeI digest and 
PCR assays. CnCYC1t contains a unique NdeI site that was used to show construct size and 





fragment presence and orientation in 5 pIBB329 and 1 pIBB332 constructs (Fig 11). Issues with 
XbaI ligation in the no-MLS cassette-terminator constructs, pIBB331 and 332, led to the use of 
SpeI to excise the CnMIP1 MLS from the +MLS,+terminator cassette plasmids. Products were 
transformed into an E. coli expression system. SalI-NdeI restriction digests were used to show 
excision of MLS (Fig 14B). The CnMIP1 predicted MLS contained a unique SalI site, allowing 
us to show that non-linearized constructs lacked the MLS. PCR was used to show that the 




Figure 10 – NdeI digests of pIBB329 and pIBB332 transformants. (A) Cassette schematics with the 
unique NdeI site highlighted in the CnCYC1t sequence. (B) pIBB332 extracts visualized on 0.8% TAE-
agarose ethidium bromide gel with digest product run for 30min. at 100V. 1kb NEB DNA ladder used for 
size comparison. Serial Cloner Virtual Cutter NdeI digest prediction to right of the ladder well. (C) 
pIBB329 extracts visualized on 0.8% TAE-agarose ethidium bromide gel with digest product run for 
30min. at 100V. 1kb NEB DNA ladder used for size comparison. Serial Cloner NdeI digest prediction 







Figure 11 – PCR assay to determine the insertion, and orientation of insertion, of the +MLS,+terminator 
cassette constructs. (A) Schematics of the pIBB329 +MLS,+CYC1t and pIBB332 +MLS,+URA5t 
constructs with primer arrows indicating those used for the orientation test. (B) 3 transformants each from 
the 1:2 and 1:4 vector-to-CYC1t molar ratio ligations, and one transformant from the URA5t ligation were 
analyzed. MLS forward (BLO318) and terminator reverse (BLO320 for CnURA5t and 322 for CnCYC1t) 
primers were used and produced the expected 1.114kb MLS-GFP-CYC1t and 1.100kb MLS-GFP-URA5t 







Figure 12 – Confirming constructs pIBB331 and pIBB332. (A) Schematics of the pIBB331 +URA5t and 
pIBB332 +CYC1t constructs with primer arrows indicating those used for the orientation test and the 
NdeI site in CYC1t. (B) SalI-NdeI digest assay of MLS-excised +terminator cassette plasmids extracted 
from E. coli. Visualized on 0.8% TAE-agarose ethidium bromide gel using 1kb NEB DNA ladder as a 
size reference. Run at 100V for 30min. NdeI-SalI Virtual Cutter predictions from Serial Cloner to right of 
ladder.  (C) PCR assay to determine the insertion and orientation of insertion of the GFP-terminator 
cassette constructs with no MLS. SpeI-GFP forward (BLO295) and XbaI-terminator reverse (BLO320 for 
CnURA5t and BLO322 for CnCYC1t) primers were used and expected to produce 1.018kb and 0.956kb 
bands for the GFP-CYC1t and GFP-URA5t amplifications respectively. Run at 100V for 30min. 
Visualized with a 0.8% TAE-agarose ethidium bromide gel using 1kb NEB DNA ladder. 
 
Confirmed constructs from the +MLS,+URA5t 1:2 molar colony #3 [pIBB328], +MLS,+CYC1t 
1:2 molar colony #1 [pIBB329,330], +URA5t subclone colony #4 [pIBB331], and +CYC1t 
subclone colony #4 [pIBB332] were saved in bacterial glycerol stocks and later used as a reagent 
for telomeric-cassette-terminator assembly and URA5 repair template assembly for CRISPR-





1. d. Creating a NEOR-CTR4p-CdMIP1 N-terminal fragment cassette. 
As was mentioned previously, the original modular cassette featured a GFP reading 
frame without a stop codon or a downstream terminator so that it could be used to tag the N-
terminal of a protein of interest (Fig 3).  However, in vivo tests for GFP expression using the 
terminator constructs did not yield evidence suggestive of a functional GFP gene. There was a 
need to trouble-shoot; additionally, concern arose that the GFP product may interfere with the 
functionality of promoter-edited genes down the line. A gene of promoter-editing interest in this 
project was MIP1. Editing and manipulation of this gene has been troublesome in previous 
studies (Walters [46]), hence the decision to remove the GFP fragment of pIBB326 for a test of 
conditional MIP1 expression using the CTR4p copper-repressible promoter.46 Primers were 
designed to amplify a 1105bp fragment of the MIP1 CDS starting at the ATG start codon and 
SpeI and XbaI at the 5’ and 3’ ends of the fragment (BLO337 and 338 in Appendix 1). This 
would allow for ligation into the pIBB326 plasmid. SpeI-XbaI digest was used to excise the GFP 
fragment and replace it with the MIP1 N-terminus following gel purification of the reagents (see 






Figure 13 – Plasmid Map of pIBB333 and 334; pIBB334 is an extract from a different colony 
from the same transformation plate with pIBB333.  
Ligation of the SAP-treated pIBB326 vector with the digested MIP1 fragment yielded 
three bacterial colonies with a kanamycin-resistant phenotype. All colonies were sampled for 
ScaI digest and PCR assays. The MIP1 fragment and pIBB326 plasmid both contain a ScaI site 
(Fig 14); digest with ScaI would produce two bands: One 5.155kb and one 2.253kb. pIBB326 
conversely would linearize into a singular 7.074kb product Accordingly, ScaI digest was used to 
show evidence for MIP1 presence in the transformants (Fig 14B). Two extracts gave the correct 
digest products while a third gave an expected pattern likely due to the relative homology 
between the SpeI and XbaI-recognized sequences. That unexpected pattern was indicative of an 
incorrect ligation product, hence we did not investigate it further. The digest product from 
colonies #1 and 2 were subjected to a PCR using primers that would confirm MIP1 fragment 






Figure 14 – Confirming the presence of the MIP1 fragment in plasmids pIBB333/334. (A) Schematic of 
cassette with annotated ScaI site and relevant primers for PCR confirmation. (B) Plasmids digested with 
ScaI. (C) PCR amplification targeting the NEOR 5’ to the MIP1 fragment; expected size of cassette is 
3.635kb. Both (B) and (C) were visualized on a 0.8% TAE-agarose ethidium bromide gel with the 1kb 
NEB DNA ladder used for size visualization. 
The two correct plasmids with the NEOR-CTR4p-MIP1 N-terminal fragment were frozen 
down at -80˚C in bacterial glycerol stocks as pIBB333 (Fig 14B #1) and pIBB334 (Fig 14B #2). 
pIBB334 was later used as a reagent for assembly of the MIP1p repair template assembly for 






2. CRISPR-Cas9 in the yeast, C. deneoformans 
 
CRISPR-Cas9 is an RNA-guided endonuclease system used to induce precise double-
stranded DNA breaks and has been adapted for use in a variety of organisms.27 These cuts 
compromise eukaryotic chromosome integrity, forcing DNA repair and/or cell death. C. 
neoformans and its sister species are haploid yeasts with single-copy, linear chromosomes.3 Fan 
and Lin developed a transient CRISPR-Cas9 protocol for the C. neoformans species complex 
that targets chromosomal sites in Cryptococcus with a single RNA guide sequence (sgRNA) 
allowing for a double-stranded cut to be induced in precise locations.14 This damage can 
facilitate reliable insertion of constructs with long stretches of homology to the damaged locus. 
Alternatively, erroneous DNA repair can catalyze gene knock-out via frame-shift mutagenesis. 
CRISPR-Cas9 can, therefore, be very useful for editing genomic sequences.16  
 
2. a. Design and assembly of cryptococcal CAS9 and URA5-targeting sgRNAs 
 
 CRISPR-Cas9 systems require the expression of the Cas9 protein and an sgRNA to affect 
site-directed DNA-damage in vivo. To express the Cas9 protein transiently in Cryptococcus, a 
PCR fragment containing a constitutive GPD promoter and the CAS9 gene with a C-terminal 
SV40 nuclear localization signal (NLS) was amplified from the pXL1-HYG-CAS9 plasmid14 
using primers BLO258 and BLO259 as shown in Fig 15C. 
The sgRNAs used in this project were expressed from DNA fragments amplified from 
the plasmid, pYF515.14 This plasmid contains a small tracrDNA-terminator fusion sequence that 
serves as a scaffold for in vitro sgDNA assembly. The sgDNA construct is expressed via a 
cryptococcal 5’ U6 promoter (CdU6p) that over-expresses the fused crDNA-tracrDNA sequence. 





using bridge primers BLO264, 265, 328, 329, and 330 to produce the desired sgDNAs (Fig 15B).  
These bridge primers contained three parts: a 5’ ~20nt fragment that overlapped with the end of 
U6p, a middle portion that was specific to the target gene (crDNA in Fig 15), and 3’ 20nt that 
corresponded to the beginning of the tracrDNA scaffold sequence (Fig 15B). Five different 
sgDNAs, sg264, 265, 328, 329, and 330, were used in this project that targeted different sections 
of the metabolic gene, URA5. The different bridge primers contained crDNA sequences that 
targeted different cut sites in the URA5 gene.  The URA5 cut sites were designed to be in the 
exonic regions to improve the chances of disruption. Two of the bridge primers (BLO264 and 
BLO265) contained the PAM sequence in the primer itself. This had an important consequence 








Figure 15 – URA5 CRISPR-Cas9 system used in this project. (A) Diagram of URA5 with annotated cut 
sites for the sgDNAs used to target damage to the gene. Green sequence in sgDNA box denotes the 
Protospacer Adjacent Motif complement included in the crDNA sequence. (B) Schematic of the 383bp 
cryptococcal sgDNA sequence. Arrows denote primers. 275bp CdU6p and 108bp tracrDNA (Left) and 
383bp sgDNA (right) PCR products visualized with 100bp Tridye Ladder DNA ladder on 2% TAE-
agarose ethidium bromid gels/ (C) pXL1 plasmid map with annotated 6.985kb CAS9 gene with GPD 
promoter (GPDp) and terminator (GPDt). 0.8% TAE-agarose ethidium bromide gel used to visualize 






 The two initial URA5-targeting sgDNAs, assembled with bridge primers BLO264 and 
BLO265 (Fig 15), resulted in poor recombination in preliminary recombination experiments 
(Appendix 5). They contained 23nt crDNA sequences complementary to sites in exon3 and 
exon2 of the URA5 reading frame, respectively. Importantly, the BLO264 and 265 crDNA 
sequences included a 3nt NCC PAM complement that would bind to the NGG PAM sequence in 
the chromosome (BLO265 in Fig 16). The PAM is recognized by the Cas9 endonuclease and 
facilitates nuclease activity.27 If the PAM is not present or not able to be bound, Cas9 cannot 
induce a double-stranded DNA break. Due to the poor effectiveness of the initial two sgDNAs, 
three new bridge primers, BLO328, 329, and 330, were designed that lacked the PAM 
complements in BLO264 and 265. The motivation for this was that removing the PAM 
compliment would make the chromosomal PAM accessible to Cas9 (BLO328 in Fig 16). One of 
the new bridge primers, BLO328, had the same sequence as that of BLO265, only lacking the 
three PAM nucleotides.  This allowed for head-to-head comparison of the effect of the PAM 
sequence in the sgRNA towards Cas9 activity.  
 
 
Figure 16 – Sequence comparison of the crDNA sequences in the bridge primers, BLO265 and BLO328. 
Green nucleotides denote the PAM targeted by each sgDNA sequence. Both are designed to guide Cas9 
to the same sequence in URA5 exon2.  BLO265 and BLO328 differ only in the presence of the PAM 






The 383bp sgDNA sequences were assembled by overlap PCR, integrating the BLO264, 
265, 328, 329, and 330 crDNA sequences between U6p and the tracrDNA scaffold sequence in 
plasmid pYF515.14 The amplified and purified CAS9 and sgRNA gene expression cassettes were 
electroporated into C. deneoformans to show in vivo functionality of the CRISPR-Cas9 system in 
the presence or absence of a homologous template for repair of the DNA damage. 
 
2. b. Disruption of URA5 with CRISPR-Cas9 mediated NHEJ. 
 
 When lacking a homologous allele, double-stranded DNA damage in chromosomal 
targets cannot undergo homology directed repair. This forces haploid cells like C. deneoformans 
to undergo nonhomologous end-joining repair (NHEJ). NHEJ is an error-prone pathway that 
tends to introduce frame-shift mutations into break sites. Since CRISPR-Cas9 induces DNA 
damage, it can be used to drive NHEJ mutagenesis. As a preliminary experiment, a 1.895kb 
NEOR fragment flanked by approximately 500bp of sequence homologous to the URA5 CDS was 
used to test homology-directed recombination via CRISPR-Cas9.  The sgRNAs used for that 
experiment were created using primers BLO264 and BLO265 containing the PAM site in their 
crDNAs; the preliminary experiment demonstrated at least a viability of the system (Appendix 
5). Preliminary results showed some promise of in vivo CRISPR activity although with low 
URA5 disruption effectiveness.  Ultimately, the process required optimization. Optimization of 
this CRISPR-Cas9 driven recombination system was first done by redesigning the bridge 
primers. BLO328, 329, and 330 did not contain the PAM were used to construct sgDNA 
sequences and were found to have a significant difference in conferring CRISPR-Cas9 activity. 
Accordingly, the sgDNAs guided Cas9 to their respective cut-sites in URA5. This was done 





forces C. deneoformans to attempt NHEJ, which tends to introduce frameshift mutations into the 
upstream cutsites. Those frameshifts were expected to knockout URA5 via misaligning the 
reading frame.28  
C. deneoformans JEC21 wild type cells were electroporated with approximately 0.7 
pmoles (2µg) of pIBB332 NEOR-CTR4p-GFP-CYC1t cassette along with 0.23 pmoles (1µg) 
CAS9 fragment and 3 pmoles (0.7µg) sgDNAs. The cassette was comprised of DNA sequences 
lacking homology to the URA5 locus and was used as a NEOR selection marker for cells that 
were successfully transformed. The pIBB332 cassette (c332) was used for this and lacked any 
meaningful homology to the locus. In theory, the exogenous DNAs encoding for CAS9, the 
sgDNA, or c332 should not recombine with the damaged chromosome. Thereby, 
nonhomologous end-joining DNA repair would be activated to disrupt the URA5 reading frame. 
Transformants were selected for by plating the cultures on YPD-NEO for three days prior to 







Figure 17 – URA5 NHEJ CRISPR-Cas9 electroporations and resultant phenotypes. c332 represents the 
pIBB332 cassette used for NEOR selection. sg264-330 represent the sgDNAs added to each sample. (A)  
YPD-NEO plates incubated for three days at 30˚C following plating of 300µL of transformed recovery 
culture. (B) 5-FOA restreaks of 15 colonies from each YPD-NEO plate incubated for two days at 30˚C.  
 
The NHEJ-driving mutagenesis system tested the accuracy of the five URA5 sgDNAs 
used in this project. By not providing a homologous repair template, we aimed to examine the 
effectiveness of the transient CRISPR-Cas9 system in producing URA5 knockout mutants by 





and BLO265 contained the PAM within their sequence, while the bridge primers BLO328, 329, 
and 330 did not. As seen in the preliminary experiments, sg264 was repeatedly found to be 
unable to facilitate URA5 disruption (Appendix 5, Fig 17B). sg265 was somewhat able to disrupt 
URA5 using both NHEJ and HDR; in the NHEJ trials, approximately 40% of the sg265 CRISPR 
transformants demonstrated a dual NEOR/5-FOAR phenotype. sg328, 329, and 330 were all 
capable of high-fidelity conferral of 5-FOAR phenotype when using the NHEJ system; 
approximate 100% of the transformants across the +sg328, 329, and 330 electroporations showed 
the dual NEOR/5-FOAR phenotype. Furthermore, an sgDNA was shown to be necessary for 
inducing the 5-FOAR phenotype; when electroporating only the CAS9 and c332 NEOR-CTR4p-
GFP-CYC1t gene cassettes, samples were not resistant to 5-FOA media, meaning URA5 and the 
uracil synthesis pathway was not knocked out in these colonies (Fig 17B). A total of 90 colonies, 
15 from each CRISPR-Cas9 NHEJ sample, were assayed for dual NEOR and 5-FOAR 
phenotypes. Colonies transformed with the CAS9-pI332-cassette only, or with sg264 added, were 
not able to grow on 5-FOA media. Six of fifteen +sg265 colonies were able to survive 5-FOA 
media, while all colonies with sg328, 329, and 330 added survived on 5-FOA (Table 1) 
Table 1 – Phenotypes induced by NHEJ repair of CRISPR-Cas9 damage to URA5. sg264-330 denote the 
sgDNAs added to individual samples, all of which contained CAS9 and a NEOR expression cassette. 
Sample Colonies Assayed NEOR 5-FOAR Dual Resistant 
CAS9 + nonhomologous cassette 15 15 0 0% 
+  sg264 15 15 0 0% 
+ sg265 15 15 6 40% 
+ sg328 15 15 15 100% 
+ sg329 15 15 15 100% 






 The discrepancy between sg265 and sg328 was particularly interesting due to their common 
target in URA5; the key difference between the two sgDNAs being a three nucleotide PAM 
complement in sg265. 
In an attempt to screen for indels and confirm each sgDNAs cut site, a 383bp fragment of 
URA5 containing the cut sites were amplified from four colonies from each +sg328, 329, and 
330 transformation (Fig 18). sg265-transformed colonies were not screened given the common 
target between sg265 and sg328.  
 
Figure 18 – PCR assay for size of URA5 Exon 1-Exon 2 fragment containing the sg328, 329, and 330 
crDNA targets. sg328-330 denotes the corresponding NHEJ system sgDNAs (A) 2% TAE-agarose 
ethidium bromide gel with URA5 fragment PCR visualized with 1kb NEB DNA ladder. WT sample is 
JEC21 positive control for size reference of wildtype fragment. (B) 2% TAE-agarose ethidium bromide 
gel with URA5 fragment PCR products send for sequencing visualized with 100bp Tridye DNA ladder. 






The presence of multiple bands in many samples and elevated bands in all samples was 
intriguing. It was possible that 11 of the 12 sampled colonies were of mixed origins, although the 
presence of a clear pattern led us to sequence three of the URA5 fragments from sg328 #2, sg329 
#3, and sg330 #4 (stars in Fig 18B). sg328 #2 was representative of the double-band pattern 
result seen in eight of the twelve gDNA extracts and was correspondingly gel purified to extract 
each band. sg329 #3 was ~450bp, a fairly unique band. sg330 #4 was representative of the 
~500bp seen in ten of the twelve samples. Sequence alignments showed, within four nucleotides 
of the targeted PAM for each sgDNA, the chromosome had integrated exogenous DNA. For 
sg329 #3, this was shown to be the tracrRNA fragment from the BLO329 sgDNA gene (Fig 19).  
 
Figure 19– Alignments of sequenced URA5 CRISPR-cutsites. (A.) Alignment of BLO67 primed sequence 
from sg329 NHEJ colony #3 (Seq2) with the URA5 wild type sequence (Seq1). Gold coloration denotes 
the aligning URA5 CDS fragment, blue denotes the tracrDNA sequence, red denotes the BLO66 and 67 
primer targets, and purple denotes the sg329 PAM. (B.) Alignment of BLO66-primed sequence from 
sg330 NHEJ colony #2’s lower band (Seq2) with a URA5 sequence (Black) where the CnCYC1t construct 
(Gold) and a fragment of the GFP sequence (Green) had inserted into the sg330 cut site (Red sequence 






For sg328 #2 ‘s lower ~500bp band, which was of similar size, this also occurred. sg328 #2’s 
~1kb band was found to be caused by the insertion of the entire sg328 sgDNA gene along with a 
fragment of the GFP-CYC1t sequence from the nonhomologous pIBB332 cassette used as a 
selection marker. This was an unexpected finding and leaves significant questions as to how 
NHEJ mechanisms choose blunt fragments for chromosomal repair. Amplification of the URA5 
locus using primers in neighboring genes and those capturing various portions of the CDS 







Figure 20 – URA5 locus size screening for CRISPR-Cas9-driven NHEJ with progressively larger 
extension times and shorter locus targets. sg328-330 represent sgDNAs used to damage URA5. (A) 
Schematic of the URA5 locus with annotated primers denoting the areas screened. Green boxes denote 
neighboring genes. (B) PCR assays of locus from neighboring genes inwards with 2.5min. extensions. 
0.8% TAE-agarose ethidium bromide gel visualizing BLO316/BLO317-primed PCR; 1kb NEB DNA 
ladder used for size reference. WT is wild-type C. deneoformans JEC21 genomic DNA sample producing 





Exon3. 0.8% TAE-agarose ethidium bromide gel visualizing BLO305/BLO306-primed PCR; 1kb NEB 
DNA ladder used for size reference. WT is wild-type C. deneoformans JEC21 genomic DNA sample 
producing the expected 689bp locus product. (D) PCR assays with 6.5min. extension spanning end of 
Exon1 to mid-Exon2. 0.8% TAE-agarose ethidium bromide gel visualizing BLO66/BLO67-primed PCR; 
visualized with 1kb NEB DNA ladder on right-most well and 100bp Tridye DNA on left-most for size 
references. WT is wild-type sample producing the expected 383bp locus product. 
 
URA5 NHEJ disruption trials yielded limited evidence for frameshift mutagenesis. 
Instead of restoring the chromosome with frameshift mutations in or around the sgDNA cut site, 
JEC21 seemingly integrated exogenous DNA fragment regardless of their nonhomology to the 
URA5 locus. The gene was disrupted by the insertion of exogenous DNA, ranging from small 
tracrDNA fragments and to large regions of the pIBB332 non-homologous cassette. Regardless, 
the CRISPR-Cas9 developed in this project was capable of inducing targeted DNA damage in 
desired chromosomal targets in vivo such that erroneous DNA repair can knock out a gene. 
 
2. c. Insertion of the modular gene cassette into URA5 with CRISPR-Cas9 by using sequence 
homology 
 
CRISPR-Cas9 has been used in other studies to insert DNA into a targeted cut site in the 
cryptococcal genome.14,35 In this project, constructs with arms homologous to the 5’ and 3’ 
UTRs of the URA5 gene were used to insert different exogenous DNAs into a cryptococcal 
chromosome. 
Lin and Fan had demonstrated that while 500bp homologous arms resulted in good rates 
of CRISPR-Cas9 driven recombination in the ADE2 gene, short homology arms of about 50bp in 
length did not.14 Accordingly, approximately 500bp fragments of the 5’ URA5 UTR ending at -
18bp from the ATG, and 3’ UTR beginning +28 from the TAA stop codon were amplified and 
attached to the flanks of the +MLS,+CYC1t (c329) and no MLS,+CYC1t (c332) modular gene 





templates that should drive recombination following CRISPR-Cas9 damage to URA5. This 
would result in the URA5 CDS being completely excised and replaced with the cassettes, thereby 
conferring geneticin-resistance due to the NEOR gene each cassette, as well as 5-fluoroorotic 
acid (5-FOA) resistance caused by uracil synthesis disruption (Δura5). Overlap PCR did, 
however, produce non-specific products that could not be resolved using a temperature gradient 




Figure 21 – Construction of the gene cassettes for insertion into URA5 by homology-driven 
recombination. (A) Schematic of the 3.61kb c329 (+MLS,+CYC1t) and 3.506kb c332 (no MLS,+CYC1t) 
cassettes and the homologous URA5 flanking sequences. (B) Gel purified URA5 5’ 525bp and 3’ 502bp 
arms visualized on a 2% TAE-agarose gel. (C) Gel purified cassettes from pIBB328 (3.588kb), pIBB329 
(3.650kb), pIBB331 (3.474kb), and pIBB332 (3.546kb) cassettes visualized on a 0.8% TAE-agarose gel. 
(D) LEFT: Column purified overlap PCR products containing the 4.637kb c329 (+MLS,+CYC1t) and 
4.543kb c332 (no MLS,+CYC1t) cassettes with attached 5’ and 3’ arms (black arrow indicating desired 
product) visualized on a 0.8% TAE-agarose gel. 
  
C. deneoformans JEC21 wild type cells were electroporated with approximately 0.70 
pmoles (2µg) of column purified overlap PCR products along with 0.23 pmoles (1µg) CAS9 





pure water and then divided, with one half being plated onto geneticin-containing (YPD-NEO) 
media and the other half being plated onto 5-FOA media.  This was to determine whether one of 
the phenotypes was a better initial selection than the other. As shown in Figure 22A, plating 
initially on YPD-NEO resulted in significant quantities of transformant colonies while initially 
plating on 5-FOA resulted in no significant growth difference from the negative control. The 
comparable growth between the 5-FOA sample plates and the negative control is suggestive that 
the colonies likely arose due to spontaneous mutations rather than targeted mutagenesis in URA5. 
Furthermore, none of the colonies assayed from these plates had a NEOR phenotype. As such, 
initial selection with NEO was used in all URA5 mutagenesis experiments in this project. This 
finding was in-keeping with the preliminary homology-driven recombination experiments using 
the smaller NEOR construct (Appendix 5). Seemingly, expression of the CRISPR-Cas9 system, 
intracellular trafficking, and genomic repair takes a protracted amount of time relative to the 
expression of NEOR resistance enzymes. 
Transformant colonies from electroporations with all five sgDNAs were screened for 
dual resistance to Geneticin and 5-FOA. A total of 150 colonies initially plated on YPD-NEO 
were assayed for 5-FOA resistance, resulting 63 of the 150 exhibiting the desired dual resistance 






Figure 22 – Selection on YPD-NEO is a better initial selection for homology-directed recombination into 
URA5. (A) YPD-NEO and 5-FOA plates following 3 and 5 days of incubation at 30˚C. c329 is the NEOR-
CTR4p-GFP-CYC1t cassette repair template and c329 is the NEOR-CTR4p-MLS-GFP-CYC1t cassette 
repair template. sg328 represents the sgDNA used. (B) Restreaks from the NEOR-CTR4p-GFP-CYC1t 
repair template NEO plate showing dual resistant phenotypes alongside relevant control strains. WT is 
JEC21 (IBCN43), 5-FOAR is a uracil synthesis knockout C. deneoformans JEC43 strain (IBCN44), and 







 Table 2 – Growth and phenotypes of the URA5 HDR excision colonies. sg264-330 denote the sgDNAs 
added to individual samples, all of which contained CAS9 and a NEOR expression cassette. c329 and 332 
denote the +MLS,+CYC1t and no MLS,+CYC1t repair template cassettes respectively. 
 






sg264 25 25 0 0% 
sg265 25 25 2 8% 
sg328 10 10 7 70.0% 
sg329 10 10 9 90.0% 
sg330 35 35 20 57.1% 
c332 
 
sg328 15 15 9 60.0% 
sg329 15 15 8 53.3% 
sg330 15 15 8 53.3% 
 
 
In order to test whether the dual phenotype was due to integration of the cassette into the 
genome, 49 dual-resistant colonies were tested for NEOR phenotype stability by passaging them 
twice on non-selective media, each passage consisting of two days of incubation at 30˚C on YPD 
before replating them on YPD-NEO. All colonies retained the geneticin-resistance phenotype, 
suggesting that the exogenous cassettes were integrated into the genome rather than being 
episomally expressed (not shown).  
43 of the dual-resistant phenotype colonies were then screened by PCR for integration of 
their respective cassette into the URA5 locus using primers BLO316 and BLO317 that amplified 
from outside the homologous URA5 flanking sequence (Fig 23B). Those that did not amplify 
with those primers were subjected to an internal cassette primer-external genomic amplification 







Figure 23 – URA5 cassette integration assays. sg328-330 represent sgDNAs used to cut URA5. (A) 
Schematic for URA5 locus homology-driven recombination. Arrows denote primers used to assaying the 
size of the locus while the line connected the template to the locus represent the regions of homology 
between repair template and URA5 UTR. Doted lines represent the sgDNA sites targetting Cas9 to the 
URA5 CDS. (B) 0.8% TAE-agarose ethidium bromide gel screening for size of URA5 locus using primers 
outside the sites of recombination. All samples are from +c332 repair template transformants. Faithful 
recombination which should elevate the 1.844kb WT locus to a 4.496kb product. WT is C. deneoformans 
JEC21 genomic DNA sample which produces the non-elevated fragment. 1kb NEB DNA ladder used for 
sized comparison. (C) Cassette integration assay targeting samples that did not yield amplifications for 
URA5 locus. This PCR used the CTR4p Forward primer (BLO293) with a reverse primer outside the the 
recombination site (BLO317) to ascertain if the repair template had been inserted into the URA5 locus. 
+c332 corresponds to the no-MLS,+CYC1t cassette repair template, which should produce a 2.401kb 
product. +c329 corresponds to the +MLS,+CYC1t cassette repair template, which should produce a 
2.511kb product. All samples visualized on 0.8% TAE-agarose ethidium bromide gel with 1kb NEB 
DNA ladder. 
 
Of the 43 sampled dual resistant colonies, 30 yielded genomic samples positive for URA5 





recombination (6/10), sg329 yielded 70% (7/10), and sg330 yielded 74% (17/23) across both 
templates. See Table 3 for a breakdown of recombination data across each sgDNA and template 
used. 
Table 3– Genotypes of the URA5 HDR excision colonies. c332 corresponds to the pIBB332 cassette 
repair template. c329 corresponds to the pIBB329 cassette repair template. sg265-330 represent the 
sgDNAs used to induce damage in the URA5 CDS. 
 









 2 1 0 1 50.0% 
sg328 5 0 0 3 60.0% 
sg329 5 1 1 3 60.0% 
sg330 18 1 4 13 72.2% 
c332 
sg328 5 1 1 3 60.0% 
sg329 5 0 1 4 80.0% 
sg330 5 0 0 4 80.0% 
 
 
 Altogether, editing URA5 using CRISPR-Cas9 was shown to be highly effective. Non-
homologous end joining repair, while chaotic, was shown to be readily able to knock out the 
gene via an error-prone mechanism. Homology-driven DNA repair was also able to knock out 
URA5 in a reliable manner; however, it was also able to precisely insert exogenous DNA 
fragments with homologous flanking sequences. The CRISPR-Cas9 reagent plasmids and strains 
with chromosomal cassette insertions were saved as glycerol stocks at -80˚C. 
 
3. Conditional regulation of CdMIP1 via CRISPR-Cas9-mediated promoter replacement. 
  
Gene manipulation can be accomplished by a variety of mechanisms. Novel genes can be 
knocked in, endogenous genes can be knocked out, and or the endogenous regulatory elements of 
a gene changed by knocking-in elements from other genes. Promoter editing is a form of 





UTR is changed.18,19,20 Thereby, the endogenous promoter in that UTR can be knocked out and a 
new promoter knocked in via recombination. The replacement promoter can be constitutive or 
conditional, driving de novo regulation of the gene without actually editing the encoded protein. 
To that end, three sgDNAs targeting the promoter of MIP1 (MIP1p) were designed in order to 
facilitate homology-driven replacement of the endogenous promoter with the conditional 
CnCTR4 promoter.  
 
3. a. Design and assembly of CRISPR-Cas9 reagents targeting the MIP1 5’ UTR 
 
In order to test the CRISPR-Cas9 system developed in this project for the capacity to 
facilitate promoter replacement, three bridging primers, BLO342, 343, and 344, were designed to 
make sgDNAs that would cut within a 200bp fragment of the 5’-UTR of MIP1 (MIP1p). 
Homology-directed DNA repair would then excise and replace that fragment with a CnCTR4p 
conditional promoter while a NEOR gene would disconnect the regulatory remnants of MIP1p 
from the CDS (Fig 24). The pIBB334 NEOR-CTR4p-MIP1 Nterm cassette (c334) was used as the 
basis for the repair template. A 726bp sequence homologous to a portion of the MIP1 5’-UTR 
and a 1106bp sequence homologous to a portion of the MIP1 CDS were added to the flanks of 






Figure 24 – Homology-driven recombination between a replacement promoter cassette and MIP1. (A) 
Schematic for recombination where blue lines denote strand-crossover between a construct and the 
genomic target. (B) crDNA sequences for sgDNAs constructed from the BLO342, 343, and 344 primers. 
(C) Schematic for the pIBB334 promoter cassette repair template. Arrows denote primers used for 
overlap PCR. 
 
Much like the URA5 CDS excision experiments, recombination was expected to occur 
such that approximately 200bp of the MIP1 5’-UTR was excised and replaced by the c334 
cassette, putting MIP1 gene expression under the control of the copper-repressible CnCTR4 
promoter. 
 
3. b. Insertion of a modular gene cassette into the MIP1 5’ UTR. 
 MIP1 is a putative, essential mitochondrial polymerase whose transcript was shown to be 
necessary for phenotype viability in C. deneoformans by RNA interference (RNAi).46 RNAi 





replacing the endogenous MIP1 promoter with CTR4p would also provide a means of knocking 
down the MIP1 transcript. Since the CTR4p is strongly down-regulated by elevated copper 
bioavailability, increasing copper concentrations could be expected to strongly decrease MIP1 
expression. Bathrocuproinedisulfonic acid (BCS) is a copper chelator that is used to deplete 
copper such that CTR4p upregulates genes.24,47 Conversely, 25µM CuSO4 with 1mM ascorbic 
acid has been previously used for optimal CTR4p down-regulation.18 If MIP1 expression is 
essential for mitochondrial viability, excessive down-regulation by CuSO4 media would result in 
cell death via respiratory dysfunction while BCS media would maintain sufficient levels of 
transcript. 
C. deneoformans JEC21 wild type cells electroporated with the repair template (2µg, 
0.74pmole), CAS9 fragment (1µg, 0.23pmole), and sgDNA (0.7µg, 3.0pmole) and plated initially 
on geneticin and BCS-containing YPD media. 105 colonies total, 35 from each +sgDNA sample, 
were then restreaked on YPD containing CuSO4 and ascorbic acid (Fig 25B) to screen for 
copper-repressible phenotype. Despite the RNAi results for MIP1 transcript knock-down, all 
colonies grew reliably under elevated copper conditions. Albeit, certain colonies had a 
distinctively lobate appearance (Fig 25B). The lobular pattern is often seen in acapsular strains 







Figure 25 – Replacement of MIP1 endogenous promoter with the conditional CTR4p promoter (A) 
Transformations on YPD-NEO-BCS plates incubated for three days at 30˚C. (B) Growth of 15 colonies 
from each transformation on YPD-NEO-BCS and YPD-CuSO4-Ascrobic Acid (Vitamin C) plates 
incubated for three days at 30˚C. JEC21 was used as a wild type (WT) control. (C) A magnified 
“acapsular” colony from the c334+sg342 YPD-CuSO4-Ascorbic Acid plate compared to the wild type.  
Table 4 – Growth and phenotypes of the CTR4p-MIP1 colonies. 




+ sg342 35 35 0 7 
+ sg343 35 35 0 9 






To determine whether the survival of the CTR4p-MIP1 recombination transformants was in spite 
of endogenous promoter replacement, the genomes of 15 colonies, 5 from each +sgDNA 
transformation, were screened by PCR. This was biased towards the irregular colonies with four 
of the five genomes tested being from the “acapsular”-appearing colonies. 
 One PCR was done using a primer in the MIP1 5’-UTR homology arm (BLO339) and 
another at the 3’ end of exon3 well outside the recombination site for the 3’ arm (BLO345). Nine 
of fifteen assayed colonies yielded elevated loci size indicative of recombination (Fig 26B). To 
confirm that the repair cassette was inserted via faithful homology-driven recombination, a PCR 
that amplified from the beginning of the CnCTR4p sequence in the repair template (BLO293) to 
the 3’ end of MIP1 exon3 (BLO345) was done as a follow-up. Reactions that did not give a 
result with 5’ arm, exon3 primers were subjected to a second PCR with the CTR4p, exon 3 






Figure 26 - PCR assays for edited MIP1 locus. sg342-344 denotes the BLO342-344 sgDNAs. (A) 
Schematic of the MIP1 recombination system. Green boxes denote the homologous sequences flanking 
the pIBB334 NEOR-CTR4p cassette shown in red. Blue lines indicate how crossing over should occur 
between the repair template and damaged chromosomal MIP1 locus.  (B) 0.8% TAE-agarose ethidium 
bromide gel with MIP1 BLO339,345 amplicon assays visualized with 1kb NEB DNA ladder. WT sample 
is wild type JEC21 positive control for size reference of the 3.479kb wildtype fragment. Correct insertion 
of cassette via recombination produces a 5.735kb product. (C) 0.8% TAE-agarose ethidium bromide gel 
with CTR4p-MIP1 exon3 amplicon assays visualized with 1kb NEB DNA ladder. Expected band size for 







Table 5 –Genotypes for MIP1 promoter replacement colonies. c334 corresponds to the pIBB334 cassette 
repair template. sg342-344 represent the sgDNAs used to induce damage in the MIP1 UTR.  









 5 0 0 5 100% 
sg343 5 0 2 3  60% 
sg344 5 1 0 4  80% 
 
The CRISPR-Cas9 system again facilitated high-fidelity, homology-driven recombination 
following damage to the MIP1 5’ UTR (Table 5). Replacement of the endogenous MIP1 
promoter was highly likely given the CTR4p-integrated genotypes that were shown via PCR. 







CHAPTER IV. DISCUSSION AND FUTURE DIRECTIONS 
 
1. The URA5 gene was edited in vivo via CRISPR-Cas9 induced damage followed by NHEJ 
mutagenesis and HDR-mediated recombination. 
 
The URA5 gene in Cryptococcus encodes the enzyme, orotidine 5’ phosphate 
decarboxylase, which plays a necessary role in the yeast’s uracil synthesis pathway. Knockout of 
this gene is sufficient to disrupt uracil synthesis in these yeasts.48 5-fluoroorotic acid is a negative 
selection agent against cells actively synthesizing uracil and is a common reagent in fungal 
genetics.49 URA5 was used in this project as a CRISPR-Cas9 target to ascertain the ability of the 
system for precision gene editing. Disruption of the reading frame and excision of the full URA5 
gene was accomplished reliably; transformations with CRISPR-Cas9 constructs induced 
resistance to 5-FOA in repeatable experiments. URA5 knock-out by homology-driven 
recombination and non-homologous end joining DNA repair were both viable editing techniques, 
though with the interesting nuance that NHEJ-driven disruption results in the random insertion of 
DNA into damage sites. Seemingly, there is no discrimination in insertion of certain DNAs over 
others, though this finding requires further study to replicate and validate. Altogether, a robust 
RNA-guided gene editing system was developed and has been shown to accurately edit the 
cryptococcal genome on-demand. 
 The expression of both an sgRNA and CAS9 was shown to be necessary for in vivo 
genome editing. When an sgDNA construct is not present, uracil knock-out was shown to not 
occur (Fig 17). This demonstrated that CRISPR-Cas9 will not randomly cut DNA within the 
genes encoding for enzymes catalyzing the uracil synthesis pathway. Conversely, when sgRNA 
was present, mutagenesis-driving damage was clearly targeted to the uracil synthesis pathway 
(Fig 17, 22). Five individual sgDNAs were designed to guide Cas9 to cut in URA5; three 





and one targeted Exon 3 (sg265). Additionally, two URA5 HDR-driving constructs were 
transformed into C. deneoformans with different combinations of sgDNAs to knock-in a NEOR 
cassette with a conditionally regulated GFP gene. Three of the sgRNAs, sg328, 329, and 330, 
were shown to reliably target DNA damage capable of NHEJ-disruption and/or homology-driven 
recombination when in the presence of homologous repair templates. sg265 was capable of low-
efficiency URA5 knock-out while sg264 was comparable to negative controls in all experiments.  
The NEOR-conditional GFP repair templates were shown to accurately recombine when URA5 
was damaged; conversely, constructs lacking homologous flanks became fragmented and were 
haphazardly inserted into damage sites (Fig 19,23). Seemingly, the difference in targeted-
mutagenesis between the sgDNAs was due to PAM design. sg264 and 265 contained 23bp 
crDNAs containing a 3bp PAM complement while sg328-330 contained 20bp crDNAs lacking 
the aforementioned PAM complement (Fig 16). 
In transformations where URA5 was targeted, generation of robust resistance to 5-FOA 
required more than three days of incubation. Initial selection on NEO-containing media appeared 
to function well, allowing us to select for cells that were successfully transformed during the 
elongated incubation. Initial selection on 5-FOA following 45 minutes, three hours, and overnight 
recovery times did not yield significant growth on 5-FOA media relative to negative controls. 
Accordingly, ∆ura5 phenotype assays were most effective when using NEO selection first, 
followed by 5-FOA selection. This is presumably due to a multiday time requirement for the 
sgDNA and CAS9 constructs to express, localize, and induce DNA repair in vivo. Time trials could 
be organized in the future to find the necessary time required, though this project found that 





NHEJ trials with sgDNAs sg328, 329, and 330 co-transformed with a NEOR episomal 
selection marker with no intrinsic homology to the target were used to try and confirm the 3-4 bp 
cut sites upstream from the targeted PAMs. These trials found perplexing, yet consistent results; 
random exogenous DNAs were found to insert within 3-4 bp of the cut sites with no discernible 
pattern or discrimination. Perhaps most interestingly, restoration of the chromosome with frame-
shift mutations was found to not occur what-so-ever; recombination with an exogenous DNA 
was the clear preference in vivo over a direct end-joining repair with the separated chromosomal 
fragment. The C. deneoformans non-homologous end joining DNA repair mechanism appears to 
take a ‘plug the hole with any means necessary’ approach to restoring chromosomal integrity and 
seems to be ‘blind’ in doing so. The organism appears to just ‘grab’ any DNA in the nucleus and 
stitch into a bluntly-cut, double-stranded damage site. This may help to explain a phenomenon 
found in literature regarding the C. neoformans species complex. 
 Previous studies in the Cryptococcus had described a common issue, or at least the 
perception thereof, when using biolistics for homology-driven insertion experiments. Those 
experiments were described as frequently suffering from high rates of off-target construct 
insertions.31 As was discussed in the Introduction, biolistic transformation has been the 
traditional means of transforming C. deneoformans. This approach involves the violent insertion 
of DNA via high energy, coated gold pellets.15 The energy involved in forcing the DNA into the 
cytoplasm poses the risk of damaging the nucleus and/or DNA within it as the kinetic energy 
transfers into cytoplasmic as well. While it has been shown that there is a low background rate of 
mutagenesis caused by biolistically-induced DNA damage, the finding that C. deneoformans 
exhibits a chaotic NHEJ repair mechanism favoring the insertion of exogenous DNA fragments 





URA5 NHEJ mutagenesis results.31 It should be noted that NHEJ is the preferred DNA repair 
mechanism of species in the C. neoformans species complex given their primarily haploid 
nature; the integration of exogenous DNA via NHEJ into chromosomal breaks could explain 
how studies using biolistic transformation suffered from off-target integrations. The relatively 
‘gentle’ approach of electroporation paired with CRISPR-Cas9 likely mitigates this risk. That 
being said, this project did not screen for off-target insertions of exogenous DNA; such screening 
would require the use of some form of Southern Blotting protocol to ascertain the presence of 
unintended insertions.50 
 More evidence and experimentation with the CRISPR-Cas9 system is desirable. 
Multiplexing experiments could be done to ascertain the viability of multiple gene edits. 
Experiments screening for potential off-target mutagenesis are also needed as follow-ups to this 
project. Despite the questions on off-target insertion and cryptococcal DNA repair that were left 
unsatisfied by Aim II, it was shown that transformed populations containing >40% 
recombination positive colonies are reliably obtainable when using a transient electroporation 
protocol targeting the URA5 gene.  
 
2. CRISPR-Cas9 crDNAs must be 20nt and not have a complement covering targeted PAM. 
 
 Cas9 endonuclease requires a network of RNAs to guide the protein towards a DNA 
target.26,27 Cas9 additionally requires a three nucleotide sequence, a Protospacer Adjacent Motif 
[PAM], immediately adjacent to the targeted DNA sequence in order to catalyze a double-
stranded DNA break. To that end, constructs containing a U6 promoter and an encoded sgRNA 
capable of guiding and activating Cas9 were designed in this project. The initial sgDNAs, sg264 





meaning that the entire crDNA sequence was 23nt long and covered the targeted chromosomal 
PAM when binding. sg328, 329, and 330 were designed later and contained 20bp crDNA 
sequences that did not contain the 3nt PAM complement like their sg264 and 265 analogs; the 
sg328-330 sgDNAs made a canonical 20nt crRNA element when transcribed.  It was shown that 
sg264 and 265 did not reliably induce high levels of URA5 knockout while sg328, 329, and 330 
readily did across nonhomologous end-joining, homology-driven recombination, and 
transformed DNA quantity trials (Fig 17, Table 2). Experiments with various DNA 
concentrations were only done in preliminary trials and should be replicated with sg328, 329, 
and 330; the high effectiveness of their sgRNAs in inducing chromosomal damage may not 
necessitate the high DNA concentrations used for obtaining CRISPR-Cas9 activity with sg264 
and sg265.  
As per Table 1, 60-80% of dual resistant strains transformed with the 20nt complement 
sgDNAs were shown to have edited genotypes. When using identical recombination templates, 
dual resistance conferral was 52% in a culture transformed with the sg330 20nt crDNA while 
transformants containing the sg264 and 265 23nt crDNAs averaged out to a 4% dual resistance. 
CRISPR-Cas9 activity is seemingly much higher when using 20nt complementary sgDNAs that 
do not contain a 3nt PAM complement. Presumably, the PAM compliment alters binding 
between the Cas9 endonuclease and targeted DNA. The PAM is absolutely necessary for Cas9 
activity. If the crRNA NCC complement obfuscates binding between Cas9 and the target’s NGG 
PAM, this could explain why sg264 resulted in no detectable URA5 knockout and sg265 resulted 









3. A modular gene cassette was assembled and tested. 
 
A gene expression cassette containing a NEOR selection marker, a CnCTR4 promoter, 
and a GFP coding frame with no stop codon or terminator was assembled for use as a reagent for 
CRISPR-Cas9 gene editing. The cassette was ligated into a pCR2.1 TOPO plasmid, making a 
final 7.074kb construct. By inserting unique sites between the fragments, the cassette was readily 
modified by inserting a variety of fragments into the construct. Altogether, the cassette made in 
Figure 19 was shown to be readily modifiable.   
 11 vectors containing the core cassette or modified variants thereof were made over the 
course of this project. The 7.074kb core cassette plasmid [NEOR-CTR4p-GFP-no stop codon] 
was assembled and the orientation of its fragment sequences confirmed using restriction digests 
(Fig 5). This initial vector was then modified by inserting a predicted MLS from CnMIP1 
between the CTR4p and GFP fragments. Four additional constructs were made by attaching a 
stop-terminator fragment to the MLS and no MLS vectors by attaching a CYC1 and a URA5 
terminator to the 3’ end of GFP.  The core cassette was also used to make another construct, a 
7.408kb NEOR-CTR4p-CdMIP1 N-terminus vector, to serve as a repair construct for the MIP1 
endogenous promoter.   
NEOR phenotype was conferred when transforming of C. neoformans KN99 and C. 
deneoformans JEC21 with these various vectors, thereby demonstrating expression of the 
1.816kb NEOR fragment. Transformation of those same strains with constructs containing 
complete GFP genes (CTR4p-(MLS)-GFP-CYC1t) did not produce fluorescent signal that was 





expression issue with the CTR4p promoter, the 3’ UTRs used as terminators, or a protein 
stability and/or folding issue with GFP; Western blotting should be used to confirm expression 
since fluorescent imaging experiments were inconclusive. In addition, it may be a good idea to 
try synthesizing cassettes with more traditional cryptococcal terminators: GPD1t, TPS1t, etc. The 
CnURA5 and CnCYC1t 3’ UTR fragments used in this study may not be sufficient to terminate 
transcription and could possibly be producing aberrated transcripts. 
 
4. MIP1 might not be a necessary gene or the CnCTR4p construct may be ‘leaky.’  
 
CdMIP1 is a gene in the nucleus that is thought to encode for the enzyme, DNA 
Polymerase Gamma [PolG]. Mitochondria rely on the import of nuclear gene products like PolG 
despite retaining some key metabolic enzymes in an attenuated genome in the matrix.51 Mip1p is 
presumed to be one such imported product and is assumed to play an essential role in 
maintaining the yeast’s mitochondria. Mitochondria are the organelles responsible for catalyzing 
cellular respiration and have rightfully been given the metaphor, ‘the powerhouse of the cell.’ 
For aerobic organisms like Cryptococcus, the role mitochondria play in respiration dictates a 
necessity for mitochondrial maintenance. Thereby, deleting a gene essential for mitochondrial 
upkeep would likely result in a nonviable phenotype. In S. cerevisiae, knockout of its MIP1 
ortholog is sufficient to abolish respiration by destabilizing the mitochondrial genome.52 
Therefore, knocking out MIP1 in Cryptococcus may induce a similar, yet deleterious disruption 
of respiration. 
 MIP1 was used in this project as a CRISPR-Cas9 target to determine the viability of the 





excision of a fragment of the MIP1 5’ UTR was accomplished via homology-directed DNA 
repair. A NEOR-CnCTR4p cassette was inserted in place of the excised UTR. The NEOR gene 
was autonomous and served as a regulatory disconnect between the remains of the endogenous 
MIP1 promoter and its CDS. This presumably made the CTR4 promoter the primary regulatory 
element for the MIP1 CDS. CTR4p is down-regulated in Cryptococcus when subjected to high 
copper environments; this ideally would have allowed the recombinant MIP1 gene to be 
knocked-down by a similar mechanism. Minimal media containing 25µM CuSO4 and 1mM 
Ascorbic Acid was found to be sufficient for CTR4p repression in Ory et al.; however, in this 
project those conditions did not result in a non-viable phenotype via MIP1 knockdown (Fig 
25).18 Genotypic screening was able to confirm high-fidelity promoter replacement using the 
CRISPR-Cas9 in the MIP1 5’ UTR (Fig 26). As such, the transient CRISPR system developed in 
this project has been shown to accurately edit the cryptococcal genome in both the CDS and 
UTRs of at least two genes. However, evidence for MIP1’s essentiality was not found.  
 As was mentioned above, knock-out of MIP1 in S. cerevisiae is known to confer a 
respiration-deficient phenotype.52 This deficiency is not fatal due to the species’ capacity to meet 
its energetic needs via fermentation. C. deneoformans is an obligate aerobe that requires 
respiration to meet its needs and therefore cannot survive without functional mitochondria.3,46 
Growth on copper-depleted YPD-NEO-400µM BCS was used to cultivate transformants for 
approximately three days before using a negative selection assay with YPD-25µM CuSO4-1mM 
Ascorbic Acid. YPD with elevated copper was shown to not be sufficient for the abolition of 
growth using both solid and liquid media. This perplexing finding requires further investigation; 
the viable phenotype on elevated-copper media possibly suggests issues with the CTR4p 





‘through’ the down-regulation induced by this promoter. There is also the possibility that the 
NEOR gene in the inserted cassette did not fully disconnect the endogenous regulatory elements 
from the MIP1 CDS, thereby hampering repression by CTR4p. Alternatively, it is possible that 
CdMIP1 is simply not an essential gene and its knock-out does not abolish respiration.  
The CTR4p sequence integrated in the pIBB326-334 constructs was shown to contain a 
minimum of two canonical CuSEs known to respond to Cuf1 regulation along with a canonical 
TATA box (See Appendix 3.e, 3.h).24 Ory et al. was able to show that similar CTR4p fragments 
containing at least two CuSEs were responsive to up-regulation by copper chelation and 
responsive to down-regulation by copper-elevation.18 That being said, the Ory et al. study did 
detect a limited amount of reporter activity suggestive of promoter ‘leakage.’ Conditional 
promoters undergoing repression may not entirely knock-down transcription, meaning that some 
transcript is still available for translation.53 Mitochondrial proteins’ transcription and translation 
are highly dynamic, highly regulated processes.54 It would not be surprising if a leaky CTR4p 
promoter allows for sufficient transcription of MIP1 to avert complete mitochondrial dysfunction 
 More investigation into the status of Mip1p protein and mRNA content in these 
transformed lines is certainly needed. A repair template with an alternative protein-tag to GFP, 
like say a His-tag, could easily be assembled and inserted into the chromosome to enable Mip1p 
quantification.55 Analysis of growth rates and respiration rates would also be useful experiments 
for determining the relative health of the transformants’ mitochondria. Furthermore, optimization 
of the GFP sequence in our pIBB328-332 constructs could also be an avenue for investigating 
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1. Primers used in project: 
 
Name: Description Sequence Restriction 
Sites 
BLO66 Cd/CnURA5 Intron1-Exon2 F Sequencing 
primer 
TCGGCAACTTTACCTTGAAGTC  
BLO67 Cd/CnURA5 Intron1-Exon2 R 
Sequencing primer 
ACCGAccatagtaccgccct  
BLO258 GDP-CAS9 F CATGCATCTAGGTCTAGAAACC  
BLO259 GPD-CAS9 R CCTCTTCACGTGGACGCTCC  
BLO260 CdU6p F TTTGCATTAGAACTAAAAACAAAGCA  
BLO261 CdU6p R CAACAGTATACCCTGCCGGTG  
BLO262 sgDNA scaffold F GTTTTAGAGCTAGAAATAGCAAG  
BLO263 sgDNA scaffold R TAAAACAAAAAAGCACCGACTCGGTGCC  
BLO264 Cd/CnURA5  sgDNA #1 bridging primer; 




BLO265 Cd/CnURA5  sgDNA #2 bridging primer; 




BLO291 Short NEOR pCR2.1 Cloning F gggAAGCTTTGCACTGAGTGTATGGTTG HindIII 
BLO292 Short NEOR pCR2.1 Cloning R aaaGGATCCGGTTTATCTGTATTAACACGGAAG BamHI 
BLO293 CnCTR4p pCR2.1 Cloning F aaaGGATCCGACCAATTGGATATTGCTGTTTC BamHI 
BLO294 CnCTR4p pCR2.1 Cloning R aaaACTAGTCCTAGGGATTGGTGAAGTCGTTGTCG AvrII,SpeI 
BLO295 GFP codon opt. pCR2.1 Cloning F cccACTAGTATGTCCAAGGGTGAGGAG SpeI 
BLO296 GFP codon opt. pCR2.1 Cloning R aaaTCTAGAGAGGTCCTCCTCGGAGATG XbaI 




















BLO304 5’ 500bp sg265 CdURA5 arm F GTTGTTTCTGAAGAGGTGAGG  
BLO305 3’ 563bp sg265 Cd/CnURA5 arm R CTTCCTGACCTCTTGCAG  
BLO306 5’ 102bp sg265 CdURA5 arm F CATGGCGTGCTTCTTTTCG   
BLO307 3’ 119bp sg265 CdURA5 arm R CAAGGAGATACCCTTGTAAG  
BLO311 CnMIP1 put. MLS pCR2.1 Cloning R gggACTAGTGCTTTGGGAAGCAGATGACGAG SpeI 




















BLO316 5’ 603bp sg264 CdURA5 arm F CACTGTCTCTGAAGCAAGACTAGC  








BLO318 CnMIP1 put. MLS pCR2.1 Cloning F gggACTAGTATGCGCAAGGCGCTTGATATTTC SpeI 
BLO319 Stop-CnURA5t pCR2.1 Cloning F aaaTCTAGATAAAGGGTTTTCTTGGATGCAG XbaI 
BLO320 CnURA5t pCR2.1 Cloning R aaaTCTAGACGATTATGAAGATTGACAGCC XbaI 
BLO321 Stop-CnCYC1t pCR2.1 Cloning F aaaTCTAGATAAATGTAGCATCTTTTTATGGGAC XbaI 
BLO322 CnCYC1t pCR2.1 Cloning R aaaTCTAGACTGACAAGGTTGGTCCACATC XbaI 
BLO325 Short NEOR pIBB103 Cloning F aaaGGTACCTGCACTGAGTGTATGGTTG KpnI 
BLO326 CnURA5t pIBB103 Cloning R aaaGGTACCCGATTATGAAGATTGACAGCC KpnI 
BLO327 CnCYC1t pIBB103 Cloning R aaaGGTACCCTGACAAGGTTGGTCCACATC KpnI 
BLO328 Cd/CnURA5  sgDNA #4 bridging primer; 




BLO329 Cd/CnURA5  sgDNA #5 bridging primer; 




BLO330 Cd/CnURA5  sgDNA #6 bridging primer; 




BLO331 CdURA5 Excision 5’ 525bp arm F GTTGCGAGAGCTAGCGCATC  










BLO334 CdURA5 Excision 3’ 502bp arm R GACTACCCGCTCTACGTGTC  










BLO337 3’ 1.106kb CdMIP1p excision homology 
arm pCR2.1 Cloning F 
gggACTAGTATGCGCAAGGCGCTCGATA SpeI 
BLO338 3’ 1.106kb CdMIP1p excision homology 
arm pCR2.1 Cloning R 
aaaTCTAGACTGAAAGATGACAGGAGATAACCAG XbaI 
BLO339  5’ 726bp CdMIP1p excision homology 
arm F 
CAACGGCGTCGTTAAGATGA  
BLO340 5’ CdMIP1p Arm-NEO Overlap F  GATTGGCCTGATTAATTGCATGAAGCTTTGCACTGAG
TGTATGG 
HindIII 
BLO341  5’ CdMIP1p Arm-NEO Overlap R CCATACACTCAGTGCAAAGCTTCATGCAATTAATCAG
GCCAATC 
HindIII 
BLO342 CdMIP1p sgDNA #1 bridging primer; 




BLO343 CdMIP1p sgDNA #2 bridging primer; 




BLO344 CdMIP1p sgDNA #3 bridging primer; 













Name: Description Markers Source 




Gene storage with GDP-CAS9 construct. Labeled as IBB320. Amp UGA 
pYF515 Gene storage for sgDNA scaffold construct. Labeled as IBB319. Amp UGA 
pIBB207 Telomeric vector for NEOR-CTR4p-GFP cassettes; 8.5kb CnMIP1 RNAi construct 
assembled for Boggs thesis. 
 Bose lab 
pIBB236 Gene storage with cryptococcal CnCTR4p fragments. Amp Bose lab 
pIBB269 Cryptococcal NEOR positive transformation control. Also can be used as template 
for NEOR. 
Amp Bose lab 
pIBB314 Gene storage with cryptococcal NEOR and GFPcodop. Amp Bose lab 
pIBB326 Gene storage for NEOR-CTR4p-GFP-nostop cassette. Amp, Kan. This work 
pIBB327 Gene storage for NEOR-CTR4p-MLS-GFP-nostop cassette. Amp, Kan. This work 
pIBB328 Gene storage for NEOR-CnCTR4p-MLS-GFP-CnURA5t cassette. Amp, Kan. This work 
pIBB329 Gene storage for NEOR-CnCTR4p-MLS-GFP-CnCYC1t cassette. Amp, Kan. This work 
pIBB331 Gene storage for NEOR-CnCTR4p-GFP-CnURA5t cassette. Amp, Kan. This work 
pIBB332 Gene storage for NEOR-CnCTR4p-GFP-CnCYC1t cassette. Amp, Kan. This work 
pIBB333 Gene storage for NEOR-CnCTR4p –CdMIP1 1.105kb Nterm cassette, SAP Colony 
#1 
Amp, Kan. This work 
pIBB334 Gene storage for NEOR-CnCTR4p –CdMIP1 1.105kb Nterm cassette, SAP Colony 
#2 
Amp, Kan. This work 
pIBB335 Telomeric pIBB207 gene storage with NEOR-CnCTR4p-GFP-CnURA5t cassette. Amp. This work 
pIBB336 Telomeric pIBB207 gene storage with NEOR-CnCTR4p -GFP-CnCYC1t cassette. Amp. This work 
pIBB337 Telomeric pIBB207 gene storage with NEOR-CnCTR4p-MLS -GFP-CnURA5t 
cassette. 
Amp. This work 
pIBB338 Telomeric pIBB207 gene  storage with NEOR-CnCTR4p-X -GFP-CnCYC1t 
cassette. 






3. Alignment Data: 
 
 
Appendix 3.A – Serial Cloner Alignment of forward primed BLO265 sgDNA sequencing reaction (Seq_2) with the 
BLO265 sgDNA schematic (Seq_1). Green highlighted sequence represented U6p, blue is the 20nt crDNA and 
PAM sequence, red is the tracrDNA. 
 
Alignment of Sequence_1:  [U6p-gRNA-URA5 265 Schematic (1).xdna] with  Sequence_2: 
[gRNA 265 Forwards (1).xdna] 
Similarity : 344/386 (89.12 %)
Seq_1  1     tttgcattagaactaaaaacaaagcatgattattacagttcatttattttttaaattgat  60
                                                    || |||||||||  |||||||
Seq_2  1     ---------------------------------------TC-TTTATTTTT--AATTGAT  18
Seq_1  61    cggcatgcatgcaaagtatacgtgcaaggacaatggtaacctgcaggtgtgaccgataat  120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  19    CGGCATGCATGCAAAGTATACGTGCAAGGACAATGGTAACCTGCAGGTGTGACCGATAAT  78
Seq_1  121   tataaccatttgttgagaatgaagaggtgaggagaaaaacaatggatgacgggaaaaaaa  180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  79    TATAACCATTTGTTGAGAATGAAGAGGTGAGGAGAAAAACAATGGATGACGGGAAAAAAA  138
Seq_1  181   taaaaaaacactgagacggcgtggaccgccgtcttatttgcttccgttatccgccaaagt  240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  139   TAAAAAAACACTGAGACGGCGTGGACCGCCGTCTTATTTGCTTCCGTTATCCGCCAAAGT  198
Seq_1  241   ggaaattgcacatacaccggcagggtatactgttgAGACCGGCATTGAAGAAGTAAGGgt  300
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  199   GGAAATTGCACATACACCGGCAGGGTATACTGTTGAGACCGGCATTGAAGAAGTAAGGGT  258
Seq_1  301   tttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtgg  360
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  259   TTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG  318
Seq_1  361   caccgagtcggtgcttttttgtttta-  386
             |||||||||||||||||||||||||| 
Seq_2  319   CACCGAGTCGGTGCTTTTTTGTTTTAA  345
Features [Seq_1]:
source [5']              : [1 : 278]
source [3']              : [282 : 386]
U6p                      : [1 : 275]
U6p_F                    : [1 : 26]
U6p_RP                   : [275 : 255]
gap [5']                 : [276 : 278]
gap [3']                 : [282 : 298]
gRNA scaffold            : [299 : 374]
sgRNAsc_FP               : [299 : 321]
sgRNAsc-RP               : [386 : 359]
TracrRNA                 : [299 : 386]
URA5 Exon 3 complement   : [276 : 298]
U6p                      : [1 : 275]
Features [Seq_2]:
URA5 Exon 3 Complement   : [234 : 256]
TracrRNA                 : [257 : 344]






Appendix 3.b – Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO291. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. 927bp 










Appendix 3.c – Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO292. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. 903bp 









Appendix 3.d – Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO293. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. 701bp 
alignment with cassette that spans, but misses a large part of, the 0.65kb CTR4p and 0.774kb GFP. Red 
sequence denotes the NEOR gene, orange is CTR4p, and green is GFP. The CTR4p canonical TATATA 
box is highlighted in purple, putative Copper Sensing Elements in cyan, and GCTG metal sensing 









Appendix 3.e – Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO294. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. 934bp 
alignment with cassette that spans the 0.65kb CTR4p and the 3’ end of the 1.816kb NEOR gene. Red 
sequence denotes the NEOR gene, orange is CTR4p, and green is GFP. The CTR4p canonical TATATA 
box is highlighted in purple, putative Copper Sensing Elements in cyan, and GCTG metal sensing 









Appendix 3.f = Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO295. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. Orange 








Appendix 3.g – Alignment of sequenced pIBB326 1:3 molar Colony No5 with primer BLO296. Sequence 
1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No5 construct. Orange 
denotes the CTR4p and green is GFP. The CTR4p canonical TATATA box is highlighted in purple, 
putative Copper Sensing Elements in cyan, and GCTG metal sensing element core sequences/possible 







Appendix 3.h – Alignment of sequenced pIBB327 1:3 molar Colony No13 with primer BLO318. 
Sequence 1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No13 
construct. Red sequence represents the 1.816kb short NEOR gene, orange is the 0.65kb CTR4p, and blue 
is the 0.108kb CnMIP1 putative MLS. The CTR4p canonical TATATA box is highlighted in purple, 
putative Copper Sensing Elements in cyan, and GCTG metal sensing element core sequences/possible 
Metal Sensing Elements in light blue. 
 
 
Appendix 3.i - Alignment of sequenced pIBB327 1:3 molar Colony No13 with primer BLO311. 
Sequence 1 (Seq_1) is the desired/designed sequence. Sequence 2 (Seq_2) is the sequenced No13 








Appendix 4 –  Design and assembly of telomeric cassette-terminator constructs 
 
 
The cassette constructs described in Results I lacked cryptococcal origins of replication 
and telomeric termini. Due to the lack of those elements, the constructs were not expected to be 
maintained nor confer stable phenotypes. To screen for expression improvements in the CTR4p-
GFP-terminator constructs, all four no MLS and +MLS cassette-terminator constructs were 
inserted into an RNAi vector, pIBB207 as described in Methods 7. Ligation was used to 
synthesize four constructs where the RNAi system had been replaced with the no MLS and 
+MLS cassette-terminator sequences. SalI digests were used to distinguish between cytoplasmic 
Cassette-terminator (Fig 27A) and KpnI digest was used to show cassette insertion (Figure 27B).  
 
Figure 27– Digests assays of the pIBB207-cassette-terminator constructs. (A) SalI digests of pIBB207-
Cassette-terminators to screen for MLS presence verses absence. 6C series are the No MLS,+CYC1t 
constructs. The 6U series are No MLS,+URA5t. 7C series is +MLS,+CYC1t. 7U series is +MLS,+URA5t. 





KpnI digests of pIBB207-cassttee,+terminators to screen for MLS presence verses absence with identical 
conditions. 
 
Restriction digests using HindIII were used to screen for insertion and orientation of the cassette 
(not shown). Confirmed constructs were saved in bacterial glycerol stocks and latter used as a 
reagent for fluorescent microscopy screening for GFP expression  
 




As a preliminary experiment to show CRISPR-Cas9 HDR functionality in in vivo C. 
deneoformans JEC21, a 1.895kb Geneticin, AKA Neomycin (NEO), resistance construct derived 
from pIBB314 plasmid and inserted into the URA5 reading frame via HDR-driven 
recombination. 
5. a. Design and assembly of NEOR HDR reagents 
 
 C. deneoformans requires extensive length of homologous sequence for recombination to 
occur.16 It had been shown that 100bp was not enough to trigger recombination, there is some 
threshold of sequence homology below 1000bp and above 100bp where recombination is prone 
to occur. Accordingly, a trial with three Homology Directed Repair (HDR) templates were 
designed, one for sg265 with 222bp of homologous sequence, another for sg265 with 1063bp of 
homologous sequence (Fig 28A), and a third for sg264 with 1266bp surrounding a NEOR 
selection marker (not shown). Amplification of the templates went ahead smoothly (Figure 28B). 








Figure 28 – URA5 sg265 NEOR recombination template. (A) Schematic of NEOR gene with URA5 
homology arms of 103/119bp and 500/563bp. Arrows denote primers and their directionality. (B) Purified 
NEOR HDR template reagents visualized on ethidium bromide agarose gels run at 100V for 30min. (Left) 
0.8% gel containing 5’ 500, 5’ 100, 3’ 563, and 3’ 119bp homology arm fragments with 100bp Tridye 
DNA Ladder. (Center) 2% gel containing 1.895bp NEOR gene visualized with 100bp Tridye DNA ladder. 
(Right) The 2.958kb NEOR-500bp/563bp URA5 flanked and 2.117kb NEOR-100bp/163bp URA5 armed 
recombination construct run on a 0.8% TAE-agarose ethidium bromide gel for 30min. 1kb NEB DNA 
Ladder used for visualization of size.   
  
5. b. HDR disruption of URA5 with CRISPR-Cas9 
 
 When chromosomal DNA is damaged and a double-stranded break (DSB) occurs, the 
chromosome becomes fragmented. This fragmentation forces cells to repair the damage or risk 
the chromosome degrading around the break-site due to the instability of the non-telomeric 
ends.55 NHEJ can rectify this in an error-prone manner; however, if a homologous allele and or 
sequence of sufficient homology is present, Homology Directed DNA Repair (HDR) can 
accurately repair the DSB and restore chromosomal integrity. The mechanism of HDR relies on 
strand invasion and recombination between the damaged chromosome and the homologous 





high fidelity. In the case of C. deneoformans, there are no natural homologous templates for 
HDR. Synthetic templates can be assembled in vitro be transform in vivo to induce HDR. The 
aforementioned templates can contain inserts that the cell will ‘repair’ into the chromosome, 
allowing for gene insertion via this pathway. This allows for selection and expression markers to 
be chromosomally inserted, producing a stable transformed line. 
Preliminary NHEJ screening proved to be problematic (not shown); hence, disruption of 
URA5 using HDR was used to test CRISPR-Cas9 effectiveness by inducing dual NEOR and 5-
FOAR phenotypes. This insertion disrupts the URA5 reading frame, disrupting the uracil 
synthesis pathway while simultaneously installing a chromosomal NEOR selection marker. Two 
URA5 disruption HDR repair templates were made for specific use with the sg265 and sg264; the 
sg265 HDR system was the only that reliably gave dual resistance phenotypes, hence the sg264 
fell into disuse after one electroporation. 
5 separate electroporations were attempted using the preliminary sg265 HDR system in 
C. deneoformans JEC21. Over those electroporations, geneticin resistance was reliably conferred 
to transformants while transformants plated on 5-FOA after the initial recovery period seemingly 









Figure 29 – YPD-NEO and 5-FOA plates inoculated with JEC21 transformed with sgDNA, CAS9, and 
NEOR recombination constructs. Plates were inoculated with recovery that was halved to inoculate each 
plate. 30°C incubation used afterwards. 
 
Over the course of all sg265 CRISPR-Cas9 URA5 disruption HDR electroporations, 215 
transformant colonies were screened for dual resistance to NEO and 5-FOA. 112 of the 215 had 
been transformed with the 500/563bp armed NEOR construct and 103 were transformed with the 
100/119bp armed NEOR construct. See Table 7 for the breakdowns of the assays. None of the 
colonies initially plated on 5-FOA had NEO resistance. 96 of the 215 colonies initially plated on 
YPD-G418 exhibited dual resistance. 
Table 6– Growth and phenotypes of the sg264 and 265 NEOR repair template electroporations. 100, 500, 
and 600bp arms denotes the length of homologous flanks surrounding the NEOR gene used during in the 
electroporation.  
 
Cassette sgDNA Total Assayed NEOR 5-FOAR Dual Resistant 
NEOR w/ 500bp arms sg265 112 112 56 50% 
NEOR w/ 600bp arms sg264 103 103 3 2.91% 
NEOR w/ 100bp arms sg265 103 103 40 38.9% 
 
A single electroporation with the sg264 HDR system produced an over-abundance of NEOR 
phenotype colonies but similarly poor initial 5-FOA colony totals. 103 colonies from the sg264 
HDR YPD-NEO plate were restreaked to assay for dual resistance; of those 103, only three were 





Genomic samples from dual phenotype colonies derived from each electroporation were 
subjected to a PCR using primers that amplified the entire URA5 sequence alongside the NEOR 
repair template. Of the 96 sg265 dual resistance colonies, 56 were subjected to genomic 
extraction and PCR screening. 35 gave expected URA5 bands while 18 gave negative 
amplifications. Two elevated URA5 amplicon sizes were found, another was abnormal but not 
elevated (Fig 30B), making for two putative recombinations using the preliminary HDR system 
(Table 7). 
 Table 7 –  Genotypes for URA5 when using sg265. 500bp and 100bp denotes the lengths of the 
homologous flanks attached to the NEOR gene used during in the electroporation. 
 







NEOR/500bp 38 26 1 1 2.63% 











Figure 30 – Loci screening of transformant URA5. (A.) Schematic for NEOR recombination with the URA5 
CDS. Arrows denote the BLO304 and 306 primers used for screening. (B.)  0.8% TAE-agarose ethidium 
bromide gels showing amplicon sizes for URA5. Arrow denotes sample with elevated URA5 size suggesting 
faithful recombination. All samples were run at 100V for 30min. Sizes visualized with 1kb NEB DNA Ladder.  
 
Two of the three dual resistant colonies sampled from the sg264 HDR system genomes sampled 
and screened for NEOR insertion into the URA5 reading frame. One yielded a negative insertion 
and the other did not amplify (Not shown). 
The sole recombinant strain produced from the sg265 URA5 disruption experiments was 
saved in a glycerol stock. Optimization of the CRISPR-Cas9 system was conducted and the 






Appendix 6 – Fluorescent microscopy of transformed C. deneoformans 
 
 Fluorescent protein fusions allow for visual tracking of targeted protein expression in 
Cryptococcus in vivo via fluorescent microscopy.57 Accordingly, the episomal transformation 
and chromosomal insertion of a Cryptococcus codon-optimized GFP gene with a terminator and 
copper-repressible promoter should theoretically allow for GFP expression and visualization. 
 
6. a. Screening for episomal GFP expression 
 
 
 The GFP coding sequence contained in the vectors assembled in Results I. C was 
complemented with a conditional promoter and two terminators. The promoter specifically was a 
copper-repressible CTR4 promoter. The terminators were the KN99 CnURA5 terminator 
(URA5t) and the KN99 CnCYC1 terminator (CYC1t), of which were added just 3’ to the reading 
frame along with a TAA stop codon. Altogether, these modifications made a complete GFP gene 
recognizable by cryptococcal transcription and translation machinery. Electroporation was used 
to transform C. deneoformans JEC21 with ScaI-linearized constructs. The vectors lacked 
replication origin sites and contained no telomeric sequences. This meant that the constructs 
were not expected to produce stable lines capable of long-term NEOR or GFP-expression. A 
fluorescent signal assay of 12 colonies total, 6 from the no MLS,+URA5t cassette and no 
MLS,+CYC1t cassette transformations was done.  The URA5t variants gave no detectable signal 
at low power and were not screened further. CYC1t constructs were screened at higher power 






Figure 31 – Episomal GFP screening of C. deneoformans transformed with +CYC1t constructs at 60x power 
under oil immersion; deconvolved using FIJI Iterative Deconvolve. (Top) Shows JEC21 negative control. 
(Middle) Shows +MLS,+CYC1t. (Bottom) Shows no MLS,+CYC1t. Left images are brightfield; right images 
are GFP. 
 
6. b. Screening for chromosomal GFP expression 
 
 With what was thought to be promising data found in transformants with the +CYC1t 
constructs, CRISPR-Cas9 was used insert the +CYC1t and +MLS,+CYC1t cassettes into the 
JEC21 genome as was seen in II B. Chromosomal insertion conferred replicative origins, 
meaning the GFP gene was actively being maintained in vivo while also being in a linear 
sequence with telomeric termini. Phenotype stability was demonstrated, giving evidence for 
chromosomal recombination. PCR was additionally used to show successful recombination. 
Samples with confirmed chromosomal insertions were used to screen for GFP expression using 
conditions described in Methods and Materials 15. b. No meaningful signal was found and 





in repressive condition (not shown). 
 
6. c. Screening for episomal telomeric GFP. 
 
 Data from F.II suggested instability in GFP expression using the pCR2.1-cassette-
terminator constructs. To attempt to improve episomal, non-maintained stability of transformed 
constructs, the +MLS,+URA5t/CYC1t and  no MLS,+URA5t/CYC1t cassettes were inserted into a 
construct containing telomeric repeat regions. Linearization produced a construct with telomeric 
termini but no replicative origins; the construct was transformed using electroporation and 




Figure 32 – Episomal GFP in C. deneoformans with telomeric construct at 60X power using oil immersion; 
deconvolved using FIJI Iterative Deconvolve. (Top Left) Shows +MLS,+CYC1t cassette in telomeric construct. (Top 
Right) Shows same construct but in pCR2.1. (Bottom Left) Shows the no MLS,+CYC1t in telomeric construct. 
(Bottom Right) Shows no same construct in pCR2.1. Left images are brightfield; right images are GFP. 
